The non-octarepeat copper-binding site of the prion protein and its potential role in prion conversion by Tran, Thanh Hoa
  
Scuola Internazionale Superiore Studi Avanzati  
(SISSA) 
 
Neurobiology Area 
 
 
 
 
 
 
The non-octarepeat copper-binding site 
of the prion protein and its potential role 
in prion conversion 
 
 
 
 
 
 
 
 Supervisor PhD candidate 
 Prof. Giuseppe Legname Thanh Hoa Tran 
 
 
 
 
 
A thesis submitted for the degree of 
Doctor of Philosophy 
in Functional and Structural Genomics 
February 2016
  
Acknowledgements 
 
Foremost, I would like to express my sincere gratitude to my supervisor Prof. 
Giuseppe Legname whom I appreciate for the vast knowledge and skills and for 
giving me the great opportunity to work in his lab. Without his continuous 
assistance, his useful advices, his patience and encouragement, I would not have 
accomplished my Ph.D. research and dissertation. 
A very special thanks go out to Prof. Juan-María Torres (Centro de 
Investigación en Sanidad Animal, Spain), Prof. Paola D’Angelo (University of 
Rome “La Sapienza”, Italy) and Dr. Fabio Moda (Istituto Neurologico Carlo Besta, 
Italy) for all the fruitful collaborations. 
In addition, I want to express my deepest thanks to all the members of the 
Prion Biology lab, Suzana, Paola, Giulia, Joanna, Elena, Xuan Nguyen, Andrea... 
for helping and supporting me during all these years, for your friendship and the 
time we spent together.  
I am grateful to Dr. Gabriele Giachin for his invaluable help on my work, 
for teaching writing a scientific paper, correcting and giving valuable advices on 
my writing. I must also acknowledge Kate Pischke for proofreading the English in 
this thesis. Thanks also go out to Mai Thao, Le Nhat, Minh Do for their helpful 
guidance at the beginning of my Ph.D. life, for sharing the time here in peaceful 
Trieste. 
I would also like to extend my thanks for the invaluable support from Tullio, 
Jessica, Micaela, Massimo, Federica, Andrea, Sandra and all SISSA staff, 
especially the Students’ Secretariat, Riccardo and Federica.   
I have a very special thanks to Lina Nguyen for standing by my side over 
last three years, taking care of me and supporting me without holding back. 
  
Finally, I wish to thank my family for their endless love, support and 
encouragement through my entire life. 
 
  
  
Abstract 
 
Transmissible spongiform encephalopathy (TSE) or prion diseases are fatal 
neurodegenerative disorders caused by a change in conformation of the prion 
protein from the normal cellular form (PrPC) to a misfolded form (PrPSc). Prion 
protein has long been known as a copper binding protein. Although the functional 
implication of copper binding to PrP is not yet clear, it is believed that copper is an 
important cofactor in prion disease.  Therefore, the aim of this work is to determine 
the potential role of copper in prion conversion. Copper can effectively bind to PrPC 
via histidine residues in the octapeptide repeats (OR) and the non-OR region located 
in the disordered N-terminal of the protein. Our hypothesis is that if copper binding 
plays a role in prion disease, removal of histidine residues in N-terminal domain 
may affect the prion conversion process. To examine this, we created a series of 
mutant murine PrP (MoPrP) molecules by replacing histidine residue at OR and 
non-OR region by tyrosine. These constructs were transfected into ScN2a cells and 
the efficiencies of prion conversion were evaluated. The results showed that 
replacing histidine by tyrosine at non-OR region led to an increasing of PrPSc 
conversion. When copper was removed by cuprizone, the construct with tyrosine at 
non-OR site (MoPrP H95Y) did not alter the level of PrPSc which meanwhile 
increased in case of the MoPrP wild-type (WT). To test these mutants in vitro, we 
produced recombinant protein, did the fibrilization assay and compared the lag 
phase. The result clearly showed that these constructs with tyrosine (H95Y, H110Y, 
H95Y/H110Y) need a shorter time to aggregate making fibrils faster than WT 
MoPrP.  In particular, N2aPrP-/- cells expressing non-OR mutations PrP 
spontaneously cause prion formation that can be detected by ASA or PMCA. 
Moreover, transgenic mice overexpressing MoPrP H95Y showed clinical signs and 
died at 100 days with PK-resistant PrP in their brain. Based on these data, we can 
  
concluded that the substitution of histidine by tyrosine at non-OR region can 
enhance PrPC-PrPSc conversion process, and the non-OR copper binding site may 
have a critical role in this process. 
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Le NT, J Narkiewicz, S Aulić, G Salzano, TH Tran, D Scaini, F Moda, G Giachin, 
and G Legname. 2015. "Synthetic prions and other human neurodegenerative 
proteinopathies". Virus Research. 207: 25-37. 
Giachin G, PT Mai, TH Tran, G Salzano, F Benetti, G Legname, et al. 2015. "The 
non-octarepeat copper binding site of the prion protein is a key regulator of prion 
conversion". Scientific Reports. 5. 
 
 
 
 
 
 
 
 
 
  
 
1 
 
Table of content 
LIST OF FIGURES ............................................................................................... 6 
LIST OF TABLES ................................................................................................. 9 
LIST OF ABBREVIATIONS ............................................................................. 10 
CHAPTER I ......................................................................................................... 14 
1.1 Prion disease ................................................................................................. 15 
1.2 The cellular prion protein (PrPC) ............................................................... 17 
1.2.1 Biogenesis and structure of PrPC ................................................................ 17 
1.2.2 Prion protein trafficking.............................................................................. 20 
1.2.3 Function of PrPC ......................................................................................... 22 
1.3 The pathological form of prion protein (PrPSc) ........................................ 24 
1.3.1 Structure of PrPSc ........................................................................................ 24 
1.3.2 The “protein-only” hypothesis .................................................................... 26 
1.3.3 Models for prion replication ....................................................................... 27 
1.4 Putative sites for PrPC-PrPSc conversion ................................................... 29 
1.5 Copper and prion diseases .......................................................................... 31 
1.5.1 Copper binding to PrPC ............................................................................... 31 
1.5.2 Copper and the function of PrPC ................................................................. 35 
1.5.3 Relationship of prion diseases and copper .................................................. 38 
1.6 Aim of study ................................................................................................. 40 
CHAPTER II ........................................................................................................ 42 
2 
 
2.1 Plasmid construction ................................................................................... 43 
2.1.1 Primer design .............................................................................................. 43 
2.1.2 Cloning of MoPrP variants plasmid for cell transfection and protein 
production .............................................................................................................. 43 
2.1.3 Cloning of HuPrP variants plasmid for EXAFS study ............................... 45 
2.1.4 Cloning of full-length MoPrP H95Y plasmid for Tg mice construction .... 45 
2.2 Cell culture and transfection ...................................................................... 46 
2.2.1 Cell lines ..................................................................................................... 46 
2.2.2 Cell growth ................................................................................................. 46 
2.2.3 Cell transfections ........................................................................................ 47 
2.3 Methods for the detection of proteins ........................................................ 48 
2.3.1 SDS –polyacrylamide gel electrophoresis (SDS-PAGE) ........................... 48 
2.3.2 Coomassie staining of gels ......................................................................... 48 
2.3.3 Western blot ................................................................................................ 48 
2.4 Biochemical assays on PrPSc and PrPC ...................................................... 48 
2.4.1 Protease-K (PK) digestion .......................................................................... 48 
2.4.2 Deglycosylation of proteins using Endo-H or PNGase-F .......................... 49 
2.4.3 Solubility assay ........................................................................................... 49 
2.5 Immunofluorescence ................................................................................... 50 
2.5.1 Immunofluorescence for the detection of PrP and organelles .................... 50 
2.5.2 Surface staining ........................................................................................... 50 
2.5.3 Endocytosis imaging ................................................................................... 51 
2.6 X-ray Absorption measurements ............................................................... 51 
2.6.1 Sample preparation ..................................................................................... 51 
2.6.2 X-ray absorption experiments ..................................................................... 51 
3 
 
2.6.3 EXAFS data analysis .................................................................................. 52 
2.7 Preparation of PrPSc or PrPres seed by sodium phosphotungstic acid 
(PTA) ..................................................................................................................... 53 
2.8 Protein misfolding cyclic amplification (PMCA) ..................................... 53 
2.9 Preparation of recombinant proteins ........................................................ 54 
2.9.1 Protein expression ....................................................................................... 54 
2.9.2 Isolation of inclusion bodies ....................................................................... 54 
2.9.3 Protein purification ..................................................................................... 55 
2.9.4 Protein refolding ......................................................................................... 55 
2.10 Monitoring the kinetics of in vitro amyloid formation ............................. 55 
2.11 Generation and detection of transgenic mice ............................................ 56 
2.12 PK immunoblot analysis of mouse brain homogenates ........................... 57 
2.13 Cell viability ................................................................................................. 57 
2.14 Statistical analysis ........................................................................................ 57 
CHAPTER III ...................................................................................................... 59 
3.1 Role of fifth copper binding site in prion conversion ............................... 60 
3.1.1 The non-OR H95Y mutation promotes prion conversion .......................... 60 
3.1.2 Cuprizone removal of copper increased level of PrPSc in MoPrP WT but not 
in H95Y .................................................................................................................. 61 
3.1.3 Localization and trafficking of H95Y mutant in N2a cell .......................... 62 
3.1.4 Effect of the H95Y mutation on the copper coordination .......................... 66 
3.1.5 Amino acid scanning reveals H95 as a “hot spot” for prion conversion .... 70 
4 
 
3.2 Non-OR mutants induce de novo generation of prions in vitro ............... 73 
3.2.1 Generation of stable N2aPrP-/- cells expressing PrP WT and non-OR 
mutants ................................................................................................................... 73 
3.2.2 The non-OR mutants share similar glycosylation patterns and proteolytic 
features as WT PrPC ............................................................................................... 74 
3.2.3 The non-OR mutants do not alter the solubility and protease resistant 
profile of PrPC ........................................................................................................ 76 
3.2.4 Substitution of Histidine by Tyrosine at non-OR copper-binding site 
accelerates fibrillization process ............................................................................ 79 
3.2.5 Non-OR mutants-derived seeds accelerates PrP polymerization in the 
amyloid seeding assay............................................................................................ 80 
3.2.6 Spontaneous PrPres generation in N2aPrP-/- cells expressing MoPrP H95Y 
as detected by PMCA............................................................................................. 82 
3.3 Spontaneous generation of prion disease in Tg mice ............................... 84 
3.3.1 Establishment of Tg mice overexpressing MoPrP H95Y ........................... 84 
3.3.2 Spontaneous disease in transgenic mice expressing MoPrP H95Y ............ 86 
CHAPTER IV ....................................................................................................... 89 
APPENDIX ........................................................................................................... 97 
A. The 3F4–epitope tag has no effect on prion conversion .............................. 98 
B. PrP mutants with the substitution of His by Tyr are not toxic to ScN2a 
cells  ....................................................................................................................... 98 
C. Substitution of His by Tyr at H110 leads to destroy 3F4 epitope ............... 99 
D. Copper coordination in the non-OR region of pathogenic mutants P101L 
and Q211P ........................................................................................................... 100 
5 
 
E. Expression and purification of recombinant PrP ...................................... 101 
F. Establishment of Tg mice expressing MoPrP H95Y .................................. 103 
BIBLIOGRAPHY .............................................................................................. 106 
 
  
6 
 
LIST OF FIGURES  
 
Figure 1. Disease-linked mutations of the prion protein ....................................... 16 
Figure 2. Three topological forms of PrP .............................................................. 18 
Figure 3. Schematic illustration of primary PrPC structure .................................... 19 
Figure 4. The three-dimensional structure of the human prion protein ................. 20 
Figure 5. Pathways of PrPC internalisation ............................................................ 21 
Figure 6. Alternative models proposed for the structure of PrPSc ......................... 25 
Figure 7. Model for the conversion of PrPC to PrPSc ............................................. 29 
Figure 8. Cell biology of PrPC and PrPSc with potential sites of conversion ......... 30 
Figure 9. A structural model of the prion protein with its full complement of copper 
 ................................................................................................................................ 31 
Figure 10. Copper coordination to the octapeptide repeat ..................................... 32 
Figure 11. Three components of copper binding to the octapeptide repeat region ... 
 ................................................................................................................................ 33 
Figure 12. Models of the Cu2+ coordination modes for the non-octapeptide repeat 
site .......................................................................................................................... 34 
Figure 13. The non-OR H95Y mutation promotes prion conversion .................... 61 
Figure 14. Cuprizone removal of copper increased level of PrPSc in MoPrP WT but 
not in H95Y ............................................................................................................ 62 
Figure 15. H95Y mutant is predominantly expressed on cell surface as wild-type 
PrPC ........................................................................................................................ 63 
7 
 
Figure 16. Substitution of histidine by tyrosine at H95 does not impair PrP 
endocytosis ............................................................................................................. 64 
Figure 17. The H95Y mutant displays intracellular accumulation in early and 
recycling endosomes .............................................................................................. 65 
Figure 18. Copper coordination in the non-OR region of HuPrP WT................... 68 
Figure 19. Copper coordination in the non-OR region of HuPrP H95Y ............... 70 
Figure 20. Effects of amino acid substitutions at His95 to prion conversion process
 ................................................................................................................................ 72 
Figure 21. Expression of PrPC in N2aPrP-/- constructs .......................................... 73 
Figure 22. The non-OR mutations share the same glycosylation patterns and 
proteolytic characteristics as PrP WT .................................................................... 75 
Figure 23. Solubility of PrP is slightly decreased in non-OR mutants .................. 77 
Figure 24. The WT PrPC and non-OR mutants displayed similar PK-resistance 
profile when expressed in N2aPrP-/- cells .............................................................. 78 
Figure 25. recMoPrP non-OR mutants dramatically promote polymerization 
processes ................................................................................................................ 80 
Figure 26. Non-OR mutants-derived seeds accelerates PrP polymerization ......... 82 
Figure 27. Detection and replication of spontaneous PrPres in N2aPrP-/- expressing 
MoPrP H95Y using PMCA. .................................................................................. 84 
Figure 28. Immunoblots of brain extracts from Tg mice. ...................................... 86 
Figure 29. Western blot of brain PrPres in mice expressing MoPrP H95Y ............ 88 
Figure 30. Model for the non-OR region molecular switch at acidic pH .............. 92 
 
8 
 
Figure S1. The 3F4–epitope tag has no effect on prion conversion ..................... 98 
Figure S2. The histidine substitutions in the OR and non-OR regions are not toxic 
for cell culture. ...................................................................................................... 99 
Figure S3. Substitution of histidine by tyrosine at H110 leads to destroy 3F4 epitope
 ............................................................................................................................. 100 
Figure S4. Comparison between copper coordination of pathological P101L, 
Q211P and HuPrP WT ........................................................................................ 101 
Figure S5. Fermentation and expression of MoPrP23-231 in E. coli BL21 (DE3)
 ............................................................................................................................. 102 
Figure S6. Purification of MoPrP23-231 ............................................................ 103 
Figure S7. Maps of plamid pJB::MoPrP(1-254, H95Y) ..................................... 104 
Figure S8. PCR assay for screening Tg mice ..................................................... 105 
 
  
9 
 
LIST OF TABLES 
 
Table 1. Human and animal prion diseases ........................................................... 15 
Table 2. Putative PrP interactors ............................................................................ 23 
Table 3. Biochemical and biophysical characteristics of PrPC and PrPSc .............. 24 
Table 4. Primers used for producing His to Tyr mutants ...................................... 43 
Table 5. Primers used for producing H95X mutants ............................................. 44 
Table 6. Transgene expression level and survival times of Tg mice expressing 
MoPrP H95Y ......................................................................................................... 87 
10 
 
 
LIST OF ABBREVIATIONS 
 
ASA: amyloid seeding assay 
BCS: Bathocuprionedisulfate 
BSE:  Bovine Spongiform Encephalopathy 
CC1: charged aminoacid cluster 1 
CC2: charged aminoacid cluster 2  
CJD: Creutzfeldt-Jakob disease 
CPZ: Cuprizone 
CWD:  Chronic Wasting Disease 
DNA: Deoxyribonucleic acid 
DRMs: detergent insoluble membrane domains 
EM: electron microscopy 
ER: endoplasmic reticulum 
fCJD: familial Creutzfeldt-Jakob disease 
FFI: Fatal familial insomnia 
FSE:  Feline spongiform encephalopathy 
FTIR: Fourier Transform Infrared Spectroscopy  
GAGs: glycosaminoglycans 
Grb2: Growth factor receptor-bound protein 2 
11 
 
GPI:  glycosylphosphatidylinositol 
GS:  GPI-anchor signal 
GSS: Gerstmann-Sträussler–Scheinker 
GndHCl:  Guanidine hydrochloride 
HD:  hydrophobic domain 
Hu: human 
HX-MS: Hydrogen-deuterium exchange mass spectroscopy 
IBs:  inclusion bodies 
IMAC: Immobilized metal ion affinity chromatography 
IPTG: isopropyl b-D-galactopyranoside 
LRP: Laminin receptor precursor 
Mo: mouse 
N2a: mouse neuroblastoma cells line 
NCAM: neuronal cell adhesion molecule 
NMR: nuclear magnetic resonance 
NMDAR: N-methyl-D-aspartate receptors  
NO:  nitric oxide 
OR: octapeptide-repeat region 
ORF: open reading frame 
PAGE:  Polyacrylamide gel electrophoresis 
PCR: Polymerase Chain Reaction 
12 
 
PMCA: Protein Misfolding Cyclic Amplification 
Prion:  Proteinaceous infectious particle 
PrP:  prion protein 
PrPC:  physiological cellular form of PrP 
PrPSc:  misfolded, pathogenic form of PrPC, also denoted as prion. 
CtmPrP: C-terminal transmembrane PrP form 
NtmPrP: N-terminal transmembrane PrP form 
SecPrP:  secretory PrP 
PrP*: partially destabilized folding intermediate of PrPC 
PK: proteinease K 
PRNP: human prion protein gene 
Prnp: prion protein gene in non human species 
PTA: phosphotungstate anion (Phosphotungstic acid) 
rec: recombinant 
RT: room temperature 
ScN2a: chronically PrPSc infected mouse neuroblastoma cells line 
SDS:  sodium dodecyl sulfate 
SEC: Size exclusion chromatoghaphy 
SHa: Syrian hamster 
SOD: superoxide dismutase 
SP:  signal peptide 
13 
 
STI-1: stress-inducible protein 1 
Tg: transgenic 
ThT: thioflavin T 
TME: Transmissible Mink Encephalopathy 
TSEs:  Transmissible spongiphorm encephalopathies 
vCJD: variant Creutzfeldt–Jakob disease 
WT: wild-type 
XAFS: X-ray absorption fine structure 
  
14 
 
 
 
 
 
 
CHAPTER I 
INTRODUCTION 
  
15 
 
1.1 Prion disease  
Prion diseases, in human and animals, are a group of fatal neurodegenerative 
diseases that are also referred to as transmissible spongiform encephalopathies 
(TSEs). They have a common feature in aberrant metabolism of the aprion protein 
(PrP) [1]. During the pathogenesis of these diseases, a cellular isoform of the prion 
protein (PrPC) adopts a pathogenic misfolded conformation denoted as prion 
(PrPSc), which accumulates in cells and causes the disease. These diseases are 
thought to mostly affect the cortex, thalamus, brain stem, cerebellum of the brain 
and other neuronal tissue [2], and can lead to progressive dementia and may also 
exhibit some cerebral ataxia [1]. Table 1 includes an overview of some TSEs in 
human and animals. The disorders can occur spontaneously, genetically or caused 
by infection [3]. 
Table 1. Human and animal prion diseases [3,4]  
Host Disease Mechanism of pathogenesis 
Humans Kuru Infection through ritualistic 
cannibalism 
Creutzfeldt-Jakob disease (CJD) Sporadic, familial or iatrogenic 
Variant Creutzfeldt–Jakob disease 
(vCJD) 
Infection from bovine prions 
Gerstmann-Sträussler–Scheinker 
syndrome (GSS) 
Familial 
Fatal Familial Insomnia (FFI) Familial 
Sheep Scrapie Infection 
Cattle Bovine Spongiform Encephalopathy 
(BSE) 
Infection or sporadic 
Cervids Chronic Wasting Disease (CWD) Infection 
Mink Transmissible Mink Encephalopathy 
(TME) 
Infection 
16 
 
Cats Feline Spongiform Encephalopathy 
(FSE) 
Infection 
 
In humans, sporadic Creutzfeldt-Jakob disease (sCJD) is the most common 
form of prion disease. It accounts for about 85% of cases recorded since 1996, with 
an annual incidence of ~1.5 cases per million worldwide [4]. About 10-15% of 
prion diseases in humans are caused by mutations in the PrP gene, PRNP [5]. Up to 
date, over 40 different mutations of the PrP gene have been shown to segregate with 
the heritable human prion diseases (Figure 1). The resulting diseases have been 
classified as three distinct clinico-pathological phenotypes: familial (f) Creutzfeldt-
Jakob disease (fCJD), Gerstmann-Sträussler–Scheinker (GSS) syndrome and Fatal 
Familial Insomnia (FFI). The acquired forms of the disease are transmitted among 
humans (iatrogenic CJD and Kuru) or from animals to humans (variant CJD or 
vCJD). Iatrogenic CJD is caused by using the infected surgical instruments in brain 
surgery or using human-derived prion-infected growth hormones [6]. Kuru was 
found in Papua New Guinea due to customary ritualistic cannibalism, which 
involved the consumption of brain material of dead relatives [7-9]. Another human 
infectious prion disease is vCJD, which is due to the consumption of prion-infected 
beef.  
 
Figure 1. Disease-linked mutations of the prion protein [3].c 
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1.2 The cellular prion protein (PrPC) 
1.2.1 Biogenesis and structure of PrPC 
The prion protein gene (PRNP in humans and Prnp in other species) is highly 
conserved across species. In mammals, the DNA sequence of the open reading 
frame (ORF) encoding PrP generally exhibits around 90% similarity[10]. The 
human PRNP comprises two exons separated by a single intron with the entire ORF 
located in the second exon [11]. The Prnp of mice, sheep and cattle contains three 
exons with the protein coding sequence located in the third exon [12-14]. The other 
exons contain untranslated sequences including the promoter and termination sites. 
The PrP promoter contains multiple copies of GC rich repeats and is devoid of 
TATA box [15]. In humans, PRNP is a single copy gene mapped in the short arm 
of chromosome 20, which corresponds to the homologous region of mouse 
chromosome 2 where Prnp is located [16]. PrPC is highly expressed within the 
central and peripheral nervous systems, although its expression varies among 
distinct cell types, neurons and brain regions [17]. Transcription and translation of 
both mRNA and protein usually correlates well and is highly regulated during 
development. PrPC is found primarily in neuronal cells but is also normally 
expressed in a variety of other tissues [18, 19].  
The human pre-pro-protein contains 253 amino acids. In the N-terminus of 
there is located a signal peptide, which regulates trafficking of the protein through 
the endoplasmic reticulum and the Golgi apparatus to the cell surface.  The protein 
is N-glycosylated at two asparagin residues (181 and 197) located in the C-terminal 
[20]. In addition, a single disulfide bridge is formed between the cysteine residues 
at position 179 and 214 [21]. Attachment of a glycosylphosphatidylinositol (GPI) 
anchor occurs at position 231 after cleavage of GPI-signal peptide [22]. The mature 
human PrP comprises amino acid 23 to 231 and it is extracellularly attached to the 
cell membrane via its GPI anchor. 
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During co-translational translocation in the ER, three topological forms of 
PrP can be synthesized. Most PrP nascent chains pass completely through the 
translocon to generate secretory PrP (SecPrP) and follow the traditional exocytic 
pathway towards the cell surface. Two transmembrane forms were generated by 
transmembrane insertion of the PrP hydrophobic domain (residues from 110 to 134) 
in the ER compartment. One form (NtmPrP) integrates into the lipid bilayer with 
the N-terminus in the ER lumen and the C-terminus retained in the cytosol, whereas 
the other form (CtmPrP) integrates in the opposite orientation [23]. The role of the 
atypical forms, CtmPrP and NtmPrP, is still not fully clarified but may be associated 
with neurotoxicity and cellular death especially in case of inherited prion diseases 
[24]. 
 
Figure 2. Three topological forms of PrP [25].  
The mature PrPC can be divided in two regions, a flexible unstructured N-
terminal region and a C-terminal globular region.   
The N-terminal domain contains two positively charged clusters (CC1 and 
CC2), one at the N-terminus and one close to the hydrophobic domain (HD, residue 
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111-134). CC1 and CC2 (residue 23-27 and 95-110, respectively) seem be involved 
in glycosaminoglycans (GAGs) [26, 27] and nucleic acids [28, 29] binding. The 
highly conserved hydrophobic domain has been shown not to serve as a 
transmembrane domain at the cell surface [30]. Nonetheless, studies using synthetic 
systems have shown that peptides from this region can span membranes and suggest 
that this could occur as part of PrPC function during cellular trafficking [31, 32]. 
Small peptides corresponding to the palindromic sequence AGAAAGA of this 
region can refold into fibrils with β-sheet structure that are toxic to cultured mouse 
hippocampal cells suggesting that the hydrophobic domain may be an important 
part of an infectious prion [33, 34]. The octapeptide-repeat region (OR) is also a 
highly conserved PrP region. The number of the repeated units can vary among 
species. In HuPrP the OR consists of one nonapeptide, PQGGGGWGQ (residues 
51-59) and four repeats of the sequence PHGGGWGQ (residues 60–91). The 
octapeptide repeats have been shown that it can be the binding sites of copper or 
other divalent cations such as zinc, nickel, iron and manganese, suggesting a 
possible role in ion regulation/signaling [35].  
 
Figure 3. Schematic illustration of primary PrPC structure. SP: signal peptide, 
CC1: charged cluster 1, CC2: charged cluster 2, OR: octapeptide repeat region, HD: 
hydrophobic domain, GS: GPI-anchor signal. 
The structure of the C-terminal ordered domain was first determined from 
mouse PrP using NMR in 1995 [36] and structures from many other species have 
since been added.  The HuPrP structure is composed of three -helices (1, 2 and 
3) and two very short β-strands which form an antiparallel β-sheet (β1 and β2). 
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Helices 2 and 3 form the bulk of the structure and are covalently bridged by a 
disulfide bond between Cys179 and Cys214.[37] 
 
Figure 4. The three-dimensional structure of the human prion protein. 
(Modified from [37]) 
1.2.2 Prion protein trafficking 
After its synthesis in the ER, PrPC is trafficked via the Golgi to the cell 
surface, where it constitutively cycles between the plasma membrane and an 
endocytic compartment [38]. This process seems to be a complex cellular event and 
various mechanisms have been proposed to explain it (Figure 5). 
In primary cultures of sensory neurons, as well as in neuroblastoma N2a cell, 
PrPC has been shown to recycle from the cell surface to endosomes via clathrin-
coated pits [39-41]. In addition, the N-terminal positively charged motif, KKRPKP, 
of PrPC has been shown to be responsible for localisation of PrPC in clathrin-coated 
pits and subsequent internalisation [38, 40]. These findings suggested that PrPC 
might be binding, via its N-terminal region, to a transmembrane protein containing 
a localisation signal for coated pits. 
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Another mechanism of PrPC internalisation has been proposed following 
PrPC localisation studies in various cell models that showed that PrPC clusters in 
caveolae or caveolae-like domains [42, 43]. However, caveolae have not been 
shown to occur on adult mammalian neurons [44], thus the role of caveolae in prion 
trafficking on neurons is unclear. 
Similar to other GPI-anchored proteins, PrPC is found mainly attached to 
low-density, detergent insoluble membrane domains (DRMs), rich in cholesterol 
and sphingolipids [45, 46], also denoted as lipid rafts. Then PrPC can internalize 
through a possible pathway that is independent of clathrin and dependent on rafts.   
 
Figure 5. Pathways of PrPC internalisation[47]. At the plasma membrane, PrPC 
can be constitutively internalized. A chief pathway of PrPC internalization in 
neuronal cells seems to depend on clathrin-mediated endocytosis (1). Caveolin-
related endocytosis and trafficking have been implicated in PrPC transport in 
Chinese hamster ovary and glial cells (2). Finally, non-clathrin and non-caveolin 
but raft-dependent endocytosis has been proposed to participate in the 
internalization of prion protein (3). 
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1.2.3 Function of PrPC 
Although PrPC was discovered over thirty years ago and has been largely 
studied, its putative physiological function is still unclear. In efforts to determine 
the function of PrPC, several lines of PrPC knockout mice have been produced and 
investigated.  
The first PrPC-null transgenic mice, called Zurich I (ZrchI), were created by 
replacing codon 4-187 with a neomycin phosphotransferase expression cassette. 
These mice showed no behavioural or learning defects [48]. A second study using 
transgenic mice, called Edinburgh made by an interruption at codon 93 of Prpn 
ORF, gave results similar to those seen for the Zurich I transgenic mice [49]. Based 
on these studies, they suggested PrPC is not necessary for normal development. 
However, contradictory results were obtained by PrP-null transgenic mice, known 
as Nagasaki, where Pnrp has been completely removed. These mice had normal 
development but at advanced ages developed ataxia and prukinje cell degeneration 
[50]. The observed phenotype was abolished by reintroduction of PrPC [50, 51], 
suggesting that PrPC have a role in the nervous system.  
Other studies involving Zurich I mice showed that these mice had lower 
anxiety levels suggesting that PrPC may help the adaptation to stress [52]. Zurich I 
mice have also shown abnormalities in their circadian rhythms and sleeping 
patterns, when PrPC was overexpressed the transgenic mice developed wild type 
phenotypes [53, 54]. In addition, aged ZrchI mice also showed impairments in short 
and long term memory [55]. These evidences for significant roles of PrPC in 
different behavioral processes suggest that PrPC could play a regulatory role in 
synapse formation and function.  
Another way to gain insight into the function of PrPC is to identify proteins that 
interact and bind to PrPC. Over the years, a number of candidates have been 
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identified as potential PrP-binding partners using many different methods, such as 
yeast two-hybrid screening, co-immunoprecipitation and cross-linking (Table 2). 
Based on this, some cellular function of PrPC have been identified, for example: 
cell adhesion [56-58], synaptogenesis [59], signalling [60], copper homeostasis 
[61], and neuroprotection [62-64]. However, the physiological relevance of most of 
the proposed interaction partners is still uncertain and need to be confirmed. 
Table 2. Putative PrP interactors [65] 
Candidate Interactor Candidate Function Identification 
Method 
Growth factor receptor-bound 
protein 2 (Grb2) 
Signal transduction (adaptor 
protein) 
Yeast two-hybrid; co-
immunoprecipitation 
Synapsin 1b Synaptic vesicle trafficking Yeast two-hybrid; co-
immunoprecipitation 
TREK-1 Two-pore K+ channel Yeast two-hybrid; co-
immunoprecipitation 
Tubulin Microtubule subunit Cross-linking 
NRAGE (Neurotrophin receptor-
interacting MAGE homologue) 
Activator of apoptosis Yeast two-hybrid; co-
immunoprecipitation 
Laminin receptor precursor 
(LRP) 
Extracellular matrix 
interactions 
Yeast two-hybrid 
Stress-inducible protein 1 (STI-
1) 
Heat shock protein Co-
immunoprecipitation 
Hsp60 Chaperone Yeast two-hybrid 
N-CAM Cell adhesion Cross-linking 
Bcl-2 Multi-domain anti-apoptotic 
regulator 
Yeast two-hybrid 
Caveolin-1 Caveolar coat Co-
immunoprecipitation 
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1.3 The pathological form of prion protein (PrPSc) 
1.3.1 Structure of PrPSc 
The key event in prion disease pathogenesis is the conversion of normal, 
native conformation PrPC to an abnormal conformation PrPSc. Although sharing the 
same sequences, the two isoforms of the prion protein bear several biophysical 
differences.  
Table 3. Biochemical and biophysical characteristics of PrPC and PrPSc 
Properties  PrPC  PrPSc  
Isoform  
Protease resistance  
Location  
Solubility  
PK-sensitivity 
 α-helices  
β-sheets  
Infectivity  
Turnover  
Monomers  
No  
Plasma membrane  
Soluble  
Sensitive  
45%  
3%  
No  
Hours  
Multimeric aggregates  
Stable core (residues 90-231)  
Intra- or extracellular  
Insoluble  
Partially resistant  
30%  
45%  
Yes   
Days  
PrPSc is insoluble in detergents and can be detected by limited protease 
digestion that results in a protease resistant molecule of around 142 amino acids 
referred to as PrP27-30. The protease-resistant core of PrPSc has been shown to form 
aggregates and amyloid, which stain with Congo red and show green-gold 
birefringence, typical of amyloids [66]. But it has been shown that the amyloid 
properties of PrPSc are not an obligatory feature of prion diseases [67] and not all 
PrPSc molecules are resistant to protease digestion [68]. The other characteristic 
used to distinguish between the two isoforms is the difference in their secondary 
structures. Fourier Transform Infrared Spectroscopy (FTIR) and circular dichroism 
studies have shown that unlike PrPC, which is predominantly α-helix (47% α-helix 
and only 3% β-sheet), PrPSc is β-sheet enriched (43% β-sheet and 30% α-helix)[33].  
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Figure 6. Alternative models proposed for the structure of PrPSc [69]. (A) The 
β-helical model, (B) the β-spiral model and (C) the parallel in-register extended β-
sheet model. 
Because PrPSc is insoluble and forms aggregates, the atomic structure of 
PrPSc is still unclear. However, several structural models have been proposed based 
on computational modeling or low-resolution biophysical techniques such as X-ray 
fiber diffraction, electron microscopy (EM) and Hydrogen-deuterium exchange 
mass spectroscopy (HX-MS). These structural models are β-helical model, β -spiral 
model and parallel in-register extended β-sheet model.  
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The first originates from cryo-electron microscopy data and structural 
modeling, and proposes that PrPSc forms left-handed β –helix motif in the region 
from residue 90 to 177, while the C-terminal region (residues 178–230) still 
maintains the α-helical folding as in PrPC (Figure 6A) [70]. In the spiral model, the 
proposed PrPSc structure derives from an all-atom explicit solvent molecular 
dynamic simulation [71, 72]. According to this model, during prion conversion the 
two native β-sheets elongate in a longer single β-strand, which forms intermolecular 
β -sheets with other PrP molecules leading to polymerization. The basic subunit of 
the oligomers was also modeled according to a trimer. In this model, the three α-
helices in PrPC maintain this conformational motif (Figure 6B). Recently, Surewicz 
et al examined by hydrogen-deuterium exchange the structural organization of 
PrPSc extracted from transgenic mice expressing unglycosilated PrPC lacking GPI 
anchor (ΔGPI) and proposed the parallel in-register extended β-sheet model. This 
model proposes a thorough refolding of PrPC into a structure composed mainly of 
β-sheets, included a continuum of short β-strands from residue ~90 to the entire C-
terminal region (Figure 6C) [73, 74]. Follow up this work, more recently, 
Groveman and colleagues also proposed the parallel in-regester model for prion-
seeded PrP amyloids by using solid-state NMR and molecular dynamics 
simulations [75]. 
1.3.2 The “protein-only” hypothesis 
The conversion of the cellular form of the prion protein to its pathogenic 
isoform is the central event of prion diseases. To explain this reaction and prion 
replication several hypotheses have been proposed. The largely accepted one is the 
“protein-only” hypothesis proposed by S. B. Prusiner [76]. The protein-only 
hypothesis, which postulates that prion propagation, results from a change in PrP 
conformation whereby PrPSc recruits endogenous PrPC in order to replicate.   
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Some of the supporting evidence comes from findings that inherited prion 
diseases are linked to mutations in the PRNP gene [77], indicating that a genetic 
disease may be able to propagate in an infectious way. Another important evidence 
comes from PrPC knockout (KO) mice, which are resistant to prions thus indicating 
that PrPC is an absolut requirement in order to develop prion diseases [78].  
The other strongest supporting evidence is the synthetic prion. In 2004 the 
production of synthetic prions via the in vitro conversion of recPrP was reported 
and they have been shown to be infectious in vivo [79]. As follow-up this 
experiment, a series of recPrP amyloid fibers were produced and intracerebrally 
injected in Tg mice overexpressing PrPC. Interestingly, different inocula were able 
to propagate in vivo and induce the formation of different prion strains [80]. 
Another method for generating synthetic prions is protein misfolding cyclic 
amplification (PMCA). This methods has improved such in vitro amplification 
systems both with regards to amplification and infectivity, and has helped 
demonstrate that infectious material can be produced in a cell-free system, which 
when inoculated into mice leads to a prion disease [81-84]. Recently, Wang et al. 
applied PMCA to produce prion starting from full-length Mo recPrP (recPMCA) 
using synthetic lipid (POPG) and RNA (isolated from mouse liver) or synthetic 
polyriboadenylic acid [85-88]. The newly generated PrPSc was found to be 
infectious, and the infectivity was maintained after several transmission studies in 
wild-type mice. The findings that several synthetic prions produced in vitro by 
different methods are able to cause prion diseases have provided the ultimate 
evidence in support of the protein-only hypothesis [89].  
1.3.3 Models for prion replication 
Two models to explain the conversion of PrPC to PrPSc have been proposed.  
28 
 
In the first model, denoted as template directed-refolding model, there is an 
interaction between exogenously introduced PrPSc and endogenous PrPC, which is 
induced to transform itself into further PrPSc. PrPSc exists as a monomer that is 
thermodynamically more stable than PrPC but a high energy barrier may prevent 
spontaneous conversion of PrPC to PrPSc [90]. There are many studies which support 
this theory; one particular study uses transgenic (Tg) mice expressing mouse PrP, 
MoPrPC, and Syrian hamster PrP, SHaPrPC [91]. When these mice were injected 
with MoPrPSc, the infectious particles facilitated the conversion of MoPrPC to 
MoPrPSc, the same was observed when the Tg mice were inoculated with SHaPrPSc. 
Thus, indicating only the PrPC with the corresponding sequence to the PrPSc present, 
undergo conformational changes. In this model, the critical step in the conversion 
is the formation of a dimer between PrPSc and PrPC, and PrPC is assumed to become 
a partially unfolding intermediate of PrPC (PrP*) before it is induced to misfold into 
PrPSc [92]. Some in vitro studies have tried to simulate this intermediate by using 2 
M guanidinium chloride or sonication [93, 94]. 
Another proposed pathway of propagation is the seeded nucleation model. 
In this model the conversion between PrPC and PrPSc is reversible, but the PrPSc 
monomer is much less stable than PrPC then the equilibrium is strongly shifted 
towards PrPC. The seed formation begins very slowly. However, once the seed has 
formed, monomeric PrPC adopt the conformation of PrPSc and can efficiently add to 
the seed. The rate-limiting step in this mechanism is not the conformational 
conversion step but the seed formation step. This step, responsible for the lag phase 
in the spontaneous conversion, can be bypassed and accelerated by addition of 
preformed PrPSc seeds [95]. 
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Figure 7. Model for the conversion of PrPC to PrPSc [90]. (A) Template directed-
refolding model, (B) seeded nucleation model. 
1.4 Putative sites for PrPC-PrPSc conversion 
Most of the prion protein is found in lipid rafts located on the outer side of 
the plasma membrane [23, 24]. PrPC serves a short period of time at the surface of 
the membrane, it has a half-life of 3 to 6 hours [96-98], after which the majority of 
the cell surface PrPC undergoes endocytosis. Several studies showed that the prion 
conversion occurs after PrPC reaches the cell surface [97, 99, 100]. In addition, PrPSc 
formation is also reduced by preventing the transport of PrPC to the plasma 
membrane [101]. Then the prion conversion is thought to take place at the cell 
surface, where the first contact between endogenous PrPC and exogenous PrPSc or 
immediately after its internalization in the endolysosomal compartment.  
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Figure 8. Cell biology of PrPC and PrPSc with potential sites of conversion[102]. 
Some PrPSc was also found in the Golgi apparatus in N2a cells persistently 
infected with RML/Chandler scrapie [103]. And also in this cell line infected with 
RML or 22L scrapie strain, increased PrPSc levels are along with increased 
retrograde transport to Golgi and ER [104]. Then another possibility for prion 
conversion is that PrPSc undergoes retrograde transport to the Golgi and ER, thereby 
disturbing the biosynthesis of PrPC and triggering the formation of the PrPSc from 
the PrPC precursor. 
There is still no thorough explanation for the necessity of PrPC to reach the 
cell membrane before being converted to PrPSc. One possibility is the 
posttranslational modifications that are necessary for prion conversion, therefore 
PrPC need to reach the plasma membrane in mature form. Another possibility is that 
PrPC will act as a receptor that mediates PrPSc internalization during infection. 
Alternatively, the plasma membrane environment might be favorable or contain 
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some factors needing for the PrPC–PrPSc interaction and conversion. For example, 
some studies showed GAGs in cell surface might bind to both PrPC and PrPSc to 
generate prion conversion [102, 105].   
1.5 Copper and prion diseases 
1.5.1 Copper binding to PrPC 
 
Figure 9. A structural model of the prion protein with its full complement of 
copper [106]. Each copper in the octarepeat domain interacts with the HGGGW. 
Electron paramagnetic resonance studies on full-length recombinant protein 
identified an additional non-octapeptide repeat binding site involving His-96 and 
His-110. 
PrPC has been found that can binds copper and PrPC can be isolated with 
copper affinity columns [107, 108]. Many studies have used recombinant prion 
protein to measure the binding affinity of different amino acid sequences of prion 
protein to copper, and most researchers would agree that copper binds specifically 
to the N-terminal domain of prion protein [109, 110]. This domain (residues 23 to 
32 
 
126) is highly disordered [111, 112] and there are about five copper binding sites 
in this domain: four in octapeptide region (residues 60-91) and one in non-
octapeptide region (residues 91-111) [113]. 
The binding of copper at octapeptide repeats binding sites.  
The octarepeat region in human prion protein is composed of a sequence of 
eight amino acids (PHGGGWGQ) repeated four times, each containing a histidine 
which is generally accepted to be the primary residue responsible for the copper 
coordination [109, 114].  This region is highly conserved and can bind four copper 
ions with identical coordination geometry [115, 116]. A crystal structure of the 
Cu(II) bound octarepeat motif (residues HGGGW) indicates a square-pyramidal 
geometry [106, 114], involving coordinating nitrogen and oxygen ligands from the 
main-chain as well as the imidazole side chain. The molecular features of the crystal 
structure are fully consistent with the structural details elucidated by Electron 
Paramagnetic Resonance (EPR) (Figure 10) [106]. 
 
Figure 10. Copper coordination to the octapeptide repeat. A. Chemical details 
of the copper-octapeptide repeat interaction, determined by electron paramagnetic 
resonance (EPR) method, B. X-ray crystal structure of the Cu2+-HGGGW 
complex. (Adapted from [106]) 
However, the copper coordination to the octapeptide repeat region was also 
dependent on the degree of copper occupancy on the protein. It has also been shown 
that at low copper-peptides ratio levels, copper ions will bind with a higher affinity 
to the octarepeats via multiple His residues [117-119]. Using the Electron 
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Paramagnetic Resonance (EPR) method, three distinct binding component have 
identified depending the copper occupancy level [106]. Component 1 dominates at 
high copper occupancy and reflects the interaction with a single His. Component 2 
is an intermediate state in which each copper is coordinated by two His residues, 
thus forming large intervening loops. Component 2 is coordination is present only 
as a transition between low copper occupancy of one atom or less and full copper 
occupancy. Component 3 presents at low copper occupancy only and it is likely to 
provide the highest affinity copper binding within the  octarepeat due to its multi-
His coordination.  
 
Figure 11. Three components of copper binding to the octapeptide repeat 
region. A. Octarepeat Cu(II) binding modes with three, two, or one coordinated 
His residues, B.  The 3 models indicating the equatorial coordination modes of 
copper binding to the octarepeat region are shown (Modified from [106, 120]) 
The binding of copper at non-octapeptide repeat binding site 
Several studies have shown that copper is able to bind outside of the 
octarepeat region of PrP [121-123]. Work by Jones highlighted these copper 
binding regions as His96 and His111 in the human protein, in the amyloidogenic 
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region between residues 90 to 126 [124]. Interestingly, the coordination of copper 
to this region changed dramatically dependent on pH. There are 3 coordination 
modes, all of them display a square planar geometry. At pH 7.5 and above, a 4N 
complex dominates, while at pH6, a ligand rearrangement shifts the coordination to 
a 3N1O configuration.  At low pH, a multi His 2N2O coordination dominates.[120]   
 
Figure 12. Models of the Cu2+ coordination modes for the non-octapeptide 
repeat site[120]. (A) Component 1 is a 4N complex that dominate at pH 7.5 and 
above, (B) Component 2 is a 3N1O complex that exists at pH 6, (C) Component 3 
is a 2N2O complex that may exist at pH 5.5. 
Copper affinity of prion protein  
Early studies suggested that the binding affinities of copper ions to PrP are 
in the micromolar (μM) range [125, 126]. The first real attempt to assess the affinity 
of copper for PrP was in the mid 1990s by Hornshaw group. Using X-ray 
fluorescence, they suggest a Kd at 6.7 μM on synthetic peptides [110] and 14 μM 
on full length protein [127]. Following this, another group used various 
spectroscopic techniques and found the affinity for copper within the octarepeat to 
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be Kd~6 μM when two octarepeat segments were present [115]. However, more 
recently, some studies showed a much stronger binding affinity, in the femtomolar 
(fM) range [35, 128]. In 2007, Treiber et al used RT-SPR (real time surface plasmon 
resonance) to assess the affinity of the octapeptide repeat for copper and found the 
Kd to be in the nanomolar range[129]. 
Regarding the non-octapeptide repeat binding site, a study of Jones et al. 
shown this site bind copper with nanomolar affinity and was higher than affinity of 
the octapeptide repeat for copper [124].  In 2007, Treiber and collaborators 
suggested the affinity of the non-octapeptide repeat site was in the mid-micromolar 
range[129]. Recently, Nadal et al. have reported that the Kd, at pH 7.4, for the 
amyloidogenic region and octarpeptide repeats (multiple His residue binding mode) 
at ~20 nM, tighter than copper binding to individual octarepeats (100 nM) [130]. 
Generally, the binding affinity of copper to PrP is around in the nanomolar range, 
and the non-octapeptide repeat sites have higher binding affinity than the 
octapeptide region sites.  
1.5.2 Copper and the function of PrPC 
Copper and PrPC expression 
Copper can modulate PrPC expression by reducing PrPC mRNA, as well as 
total PrPC protein [131]. Along with these changes in PrPC expression, the amount 
of PrPC shed into the extracellular media was also significantly increased.  This 
effect of copper on PrPC was eliminated by co-treatment with a copper chelator 
termed cuprizone, indicating that these effects required extracellular copper.  
Another study has shown that the copper additions significantly increased PrPC 
levels in neuronal cells [132]. Furthermore, PrPC expression levels returned to 
normal when co-treatment with bathocuprionedisulfate (BCS), another copper 
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chelator. The ability of copper to modulate the PrPC expression levels suggest a role 
of copper in the physiological function of PrPC. 
Copper uptake 
PrPC concentrate at presynaptic membranes, where copper ions are also 
highly localised [133]. The fact that mice devoid of PrPC harbour 50% lower copper 
concentrations in synaptosomal fractions than their WT mice suggests that PrPC 
plays a role in the regulation of the copper concentration at the synaptic region of 
the neuron and also in the re-uptake of metal into the presynaptic cleft [134]. Recent 
studies show that prion protein has a high degree of structural homology with the 
ZIP family of zinc ion transporters [135] and altered PrP expression perturbs copper 
metabolism [136].  Furthermore, copper added to cultured neuroblastoma cells 
promotes the endocytosis of the PrPC [137, 138]. Hence, it can be hypothesized that 
the transport of copper from the extracellular to the intracellular compartment is 
operated through PrPC internalisation. Alternatively, PrPC may act as a copper 
buffer at the synaptic cleft, capturing copper and handling it over to another 
membrane transporter. 
Copper and neuroprotective role of PrPC  
Based on PrPC localization in synaptic region and its high affinity for copper 
ions, several research lines suggest that PrPC is a neuronal metalloenzyme with 
SOD-like activity, enabling its effective functioning as an antioxidant in the central 
nervous system [139]. Recombinant PrP as well as immunoprecipitated murine 
PrPC have been shown to harbour the activity of a copper/zinc-dependent 
superoxide dismutase (SOD), endowing PrPC with antioxidant capacities [140]. 
Copper has to be present during PrPC folding for the protein to show SOD activity. 
In line with these results, the activity of cytosolic SOD has been reported that 
decreased in the brains of PrPo/o mice [139] but increased in mice that 
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overexpressing PrPC [141]. Moreover, SOD activity in brain lysates from WT mice 
was reduced after PrPC depletion using anti-PrPC antibodies [142]. However, other 
group showed that the direct assays of SOD activity were inconsistent with some 
measurements identifying weak dismutase function [141] and others found no 
activity [143, 144]. These authors proposed that PrPC may have an antioxidant 
function, but opposed to enzymatic function, in which PrP binds extracellular 
Cu(II), thus quenching copper’s intrinsic redox activity. Although the role of PrPC 
as a SOD or as an oxidative stress-reducer is not yet definitive, PrPC clearly has a 
neuroprotective role. 
In addition, several studies have also shown that PrPC may protect against 
excitotoxic stress in neurons.  Removing a 20 residues (105 – 125) from the N-
terminal domain of PrP (ΔCR PrP) causes mice to develop the degeneration of 
cerebellar granule neurons, a typical symptom of excitotoxic stress. This effects of 
ΔCR PrP can be rescued by co-expression of WT PrP [145, 146]. Other studies 
using PrPo/o mice have revealed that PrPC expression at synapses exerts 
neuroprotection by modulating neuronal excitability [64, 147, 148]. Excitotoxicity 
occurs in PrPo/o mice as aberrant activity of the N-methyl-d-aspartate receptors 
(NMDAR) that allows entry of Ca(II) ions into the cell causing nerve cell damage 
and death.  Coexpression of WT PrPC reverses this effect, allowing PrPC to interact 
and inhibit the NDMAR, leading to suppress excitotoxicity and PrPC requires 
copper for this process [64, 149]. Recently, Gasperini et al. showed that PrPC exerts 
copper-dependent neuroprotection by inhibiting NMDAR through S-nitrosylation, 
a post-translational modification resulting from the reaction of nitric oxide (NO) 
with cysteines [150]. Comparing WT and PrPo/o mice, they found that NMDAR S-
nitrosylation decreased in PrPo/o mice and the treatment with copper chelator 
decreased NMDAR S-nitrosylation in WT but not in PrPo/o mice.  Based on these 
results, they proposed a neuroprotective mechanism of PrPC, in which PrPC-bound 
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copper ions act as electron acceptors in the reaction between NO and NMDAR 
cysteine thiols. The consequent S-nitrosylation inhibits the NMDAR and reduces 
the neurotoxic effect caused by its overactivation. 
1.5.3 Relationship of prion diseases and copper 
Ever since before the theorem of prion, the relationship of prion diseases and 
copper metabolism has been already proposed and studied. In early 1970s, Pattison 
and Jebbett have shown that cuprizone, a copper chelator, as the cause of 
spongiform lesions in the rodent brain that share a similar histopathology of mouse 
scrapie [151]. Kimberlin and Millson also found that cuprizone could delay or 
prevent (with very low inoculation titers) the terminal illness in mice affected by 
scrapie [152], although their results were not completely reproducible. After falling 
into ignorance for about two decades, since 2000s, the topic on copper-prion 
diseases came back into hot debate since copper was found to bind PrPC [125].  
On the basis of previous studies that PrP expression level is strongly 
correlated with the incubation time [53, 78] and is affected by copper [132, 153, 
154] a number of authors have proposed the hypotheses about the impacts of copper 
on prion disease incubation time. Various in vivo experiments have been designed 
to test this hypothesis and resulted in controversial conclusions about the positive 
or negative role of copper in prion diseases. Some studies showed that copper plays 
a positive role in prion diseases since supplementing copper prolong the survival 
time in infected animals [155, 156]. On the contrary, Canello and collaborators, 
using a chimeric mouse/human model of E200K on Creutzfeldt-Jakob disease, 
revealed that copper supplementation resulted in disease acceleration [157]. 
Additionally, Sigurdsson and colleagues found that copper chelation help delays 
the onset of the disease [158].  
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On the other hand, copper has been shown to have the capacity to convert 
PrP into protease-resistant and detergent-insoluble forms but in a different 
conformation than PrPSc [159]. A study of Treiber and colleagues on yeast PrP also 
showed that yeast grown in copper supplemented media contained PK-resistant PrP 
[160]. This suggests that copper treatment could induce formation of PK-resistant 
PrP. Similarly, Nishina and collaborators found the capacity of copper to modulate 
the protease resistance of PrPSc, showing that the absence of copper renders PrPSc 
20 times more sensitive to PK digestion [161]. Copper also can helps PrPSc to 
recover its infectivity and biochemical properties after reversible denaturation by 
GdnHCl. However, copper inhibits PrPC-PrPSc conversion in PMCA [162] and 
formation of fibrils made from recombinant PrP in an amyloid seeding assay (ASA) 
[163]. 
In transgenic mice studies, mice expressing PrP without the octapeptide 
repeats have extended incubation times despite high PrP expression levels [164].  
Owen et al. showed that the insertion of additional two to nine octapeptide repeats 
cause familial prion disease in humans [165]. However, the same study proved that 
the deletion of an octapeptide repeat did not lead to disease [165].  Interestingly, 
another report showed that an elderly woman with two-octapeptide repeat deletion 
showed a rapidly progressive dementia consistent with Creutzfeldt-Jakob disease 
[166].  
In conclusion, several studies have been performed with the aim to find a 
link between copper and PrPSc formation, with partially contradictory results. These 
studies clearly support the role of copper with PrPC in prion disease, but it still 
remains unclear whether the interaction between PrPC and copper facilitates or 
inhibits prion formation. Therefore, the topic on copper-prion disease relationship 
remains huge potential for further investigation.  
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1.6 Aim of study 
The conversion of normal form (PrPC) into the infectious form (PrPSc) is the 
key event in prion diseases. Althought there have been numerous studies, the 
mechanism of prion conversion still remains elusive. Pathological point mutations 
may help to disclose these molecular mechanisms. Most point mutations linked to 
inherited prion diseases are clustered in C-terminal globular domain, these 
mutations may affect secondary structure elements and structure flexibility of the 
globular domain [167-169] and also accelerate the misfolding process in vitro [170-
172]. Several structural studies on this globular domain proposed a role of the β2-
α2 loop as dynamic “switch” that able to modulate the PrPC-PrPSc conversion [173, 
174]. Interestingly, some point mutations located in the unstructured N-terminal 
domain. These mutations cause the disease without affecting the kinetics of fibril 
formation in vitro [175, 176]. Moreover, there is little evidence for a direct 
molecular effect of the mutations in the N-terminus on the globular structure of PrPC 
[169]. This suggests that N-terminal mutations might affects to the PrPSc fomation 
in different way, indicating the potential critical impact of N-terminal domain on 
prion conversion.  
The N-terminal domain of PrP has been shown to have high affinity with 
copper [109, 110] and the copper binding seems to be involved in physiological 
functions of PrPC [134, 140, 149, 150] as well as in PrPSc formation and replication 
[155, 156, 162, 163]. The treatment of the infectious prion with proteinase K cuts 
PrPSc at approximately residue 90 but without loss of infectivity, moreover the Tg 
mice studies also showed the OR copper-binding sites were not essential for prion 
infectivity [53], suggesting that this region might not play a role in the prion 
diseases. Meanwhile, the non-OR region may be relevant because of its location. 
The non-OR region locates in the protease-resistant core of PrPSc and is adjacent to 
the hydrophobic region that contained the palindromic motif sequence 
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AGAAAAGA involving in structural changes during the early stage of prion 
conversion [177]. In addition, the Tg mice expressing the PrP mutant in which non-
OR and hydrophobic region were deleted developed the diseases with cerebral 
disorders [178, 179]. The interaction of copper with a peptide including the non-
OR and palindromic motif also induced β-sheet formation and aggregation of this 
segment [180, 181]. These observations raised the question whether the non-OR 
copper-binding site may have an important role in prion conversion. Therefore, my 
PhD work aims to evaluate the relationship between the non-OR copper binding 
site and the prion conversion. The major parts of this work are:   
- Evaluating the role of copper binding site in OR and non-OR regions on 
PrPC to PrPSc conversion using ScN2a cell conversion assay. In addition, we used 
synchrotron-based X-ray absorption fine structure (XAFS) technique to study the 
coordination geometries of Cu(II) in H95Y mutant and the pathogenic mutants 
(P101L and Q211P, in mouse numbering) and we compared these findings with the 
WT to find the correlation between the copper coordination and the prion 
conversion. 
- Investigating the spontaneously conversion of non-OR mutants that were 
expressed in N2aPrP-/- cells. The amyloidogenic potential of recombinant non-OR 
mutants was also analysed by fibrillization assay. 
- Investigating the spontaneous generation of prion disease in Tg mice. 
The Tg mice expressing H95Y mutant were established and analysed the lifespan, 
behavior, clinical signs and then examined the brain tissue to determine whether 
they can develope prion diseases. 
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2.1 Plasmid construction 
2.1.1 Primer design  
Primers were designed using the Primer Blast (NCBI) and QuikChange 
Primer Design (Agilent Technologies).  
2.1.2 Cloning of MoPrP variants plasmid for cell transfection and protein 
production 
The mutations were inserted into pcDNA::MoPrP(1-254)WT, 
pcDNA::MoPrP(1-254)WT3F4 or pET::MoPrP(23-230) by using the QuikChange 
mutagenenis kit (Agilent Technologies) according to manufacturer’s instructions.  
PCR parameters were as follows: melting temperature: 95 °C for 30 sec; 
annealing temperature: 55 °C for 45 sec ; extension temperature: 68 °C for 5 min. 
These three steps were cycled 16 times. Strand extension was completed at 72 °C 
for 5 min and reactions cooled to 4 °C. 10 ng of template DNA and 2.5 U PhuUltra 
DNA polymerase was used in each reaction. PCR products were digested by DpnI 
(1 μL per 20 μL PCR reaction for 1 hour at 37 oC) prior to transformation into XL-
1 Blue supercompetent cells. 
Table 4. Primers used for producing His to Tyr mutants 
Primer  Sequences 
H60Y-F CAGCCCTACGGTGGTGGCTGGGGACAA 
H60Y-R TTGTCCCCAGCCACCACCGTAGGGCTG 
H68Y-F GGGGACAACCCTATGGGGGCAGCTGG 
H68Y-R CCAGCTGCCCCCATAGGGTTGTCCCC 
H76Y-F AGCTGGGGACAACCTTATGGTGGTAGTTGGG 
H76Y-R CCCAACTACCACCATAAGGTTGTCCCCAGCT 
H84Y-F TGGGGTCAGCCCTATGGCGGTGGATGG 
H84Y-R CCATCCACCGCCATAGGGCTGACCCCA 
H95Y-F CAAGGAGGGGGTACCTATAATCAGTGGAACAAGC 
H95Y-R GCTTGTTCCACTGATTATAGGTACCCCCTCCTTG 
H110Y-F AAAAACCAACCTCAAGTATGTGGCAGGGGCTGC 
H110Y-R GCAGCCCCTGCCACATACTTGAGGTTGGTTTTT 
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Plasmid DNA was purified using the QIAprep Miniprep Kit (Qiagen). All 
the constructs were verified by sequencing. 
The pET11a expressing the full length MoPrP(23-230) were kindly provided 
by the group of Prof. Jesús Requena (Universidade de Santiago de Compostela, 
Spain). 
Table 5. Primers used for producing H95X mutants 
Primer Sequences 
H95R-F CAAGGAGGGGGTACCAGGAATCAGTGGAACAAGC 
H95R-R GCTTGTTCCACTGATTCCTGGTACCCCCTCCTTG 
H95KF CAAGGAGGGGGTACCAAGAATCAGTGGAACAAGC 
H95K-R GCTTGTTCCACTGATTCTTGGTACCCCCTCCTTG 
H95D-F CAAGGAGGGGGTACCGACAATCAGTGGAACAAGC 
H95D-R GCTTGTTCCACTGATTGTCGGTACCCCCTCCTTG 
H95E-F CAAGGAGGGGGTACCGAGAATCAGTGGAACAAGC 
H95E-R GCTTGTTCCACTGATTCTCGGTACCCCCTCCTTG 
H95S-F CAAGGAGGGGGTACCAGCAATCAGTGGAACAAGC 
H95S-R GCTTGTTCCACTGATTGCTGGTACCCCCTCCTTG 
H95T-F CAAGGAGGGGGTACCACCAATCAGTGGAACAAGC 
H95T-R GCTTGTTCCACTGATTGGTGGTACCCCCTCCTTG 
H95N-F CAAGGAGGGGGTACCAACAATCAGTGGAACAAGC 
H95N-R GCTTGTTCCACTGATTGTTGGTACCCCCTCCTTG 
H95Q-F CAAGGAGGGGGTACCCAGAATCAGTGGAACAAGC 
H95Q-R GCTTGTTCCACTGATTCTGGGTACCCCCTCCTTG 
H95C-F CAAGGAGGGGGTACCTGCAATCAGTGGAACAAGC 
H95C-R GCTTGTTCCACTGATTGCAGGTACCCCCTCCTTG 
H95G-F CAAAAACCAACATGAAGGCTATGGCAGGGGCTGCGG 
H95G-R CCGCAGCCCCTGCCATAGCCTTCATGTTGGTTTTTG 
H95P-F CAAGGAGGGGGTACCCCTAATCAGTGGAACAAGC 
H95P-R GCTTGTTCCACTGATTAGGGGTACCCCCTCCTTG 
H95A-F CAAGGAGGGGGTACCGCCAATCAGTGGAACAAGC 
H95A-R GCTTGTTCCACTGATTGGCGGTACCCCCTCCTTG 
H95V-F CAAGGAGGGGGTACCGTGAATCAGTGGAACAAGC 
H95V-R GCTTGTTCCACTGATTCACGGTACCCCCTCCTTG 
H95I-F CAAGGAGGGGGTACCATCAATCAGTGGAACAAGC 
H95I-R GCTTGTTCCACTGATTGATGGTACCCCCTCCTTG 
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H95L-F CAAGGAGGGGGTACCCTGAATCAGTGGAACAAGC 
H95L-R GCTTGTTCCACTGATTCAGGGTACCCCCTCCTTG 
H95M-F CAAGGAGGGGGTACCATGAATCAGTGGAACAAGC 
H95M-R GCTTGTTCCACTGATTCATGGTACCCCCTCCTTG 
H95F-F CAAGGAGGGGGTACCTTCAATCAGTGGAACAAGC 
H95F-R GCTTGTTCCACTGATTGAAGGTACCCCCTCCTTG 
H95W-F CAAGGAGGGGGTACCTGGAATCAGTGGAACAAGC 
H95W-R GCTTGTTCCACTGATTCCAGGTACCCCCTCCTTG 
2.1.3 Cloning of HuPrP variants plasmid for EXAFS study 
P101L and Q211P mutations were inserted into pET::HuPrP(90-231) by 
using the QuikChange mutagenenis kit (Agilent Technologies) according to 
manufacturer’s instructions. We used the following primers for the mutagenesis: 
- P101L-F: 5'-TGG TTT TTG GCT TAC TCA GCT TGT TCC ACT GA-3' 
- P101L-R: 5'-TCA GTG GAA CAA GCT GAG TAA GCC AAA AAC CA-3' 
- Q211P-F: 5’-CGC GTG GTT GAG CCG ATG TGT ATC ACC C-3’  
- Q211P-R: 5’- GGG TGA TAC ACA TCG GCT CAA CCA CGC G-3’ 
Plasmid DNA was purified using the QIAprep Miniprep Kit (Qiagen). All 
the constructs were verified by sequencing. 
2.1.4 Cloning of full-length MoPrP H95Y plasmid for Tg mice construction 
The MoPrP(1-254, H95Y) was amplified from plasmid pcDNA::MoPrP(1-
254, H95Y) by PCR using these primer: 
- 5’Bsi-MoPrP: 5’-CCT AGT GGT ACC TCG TAC GCA GTC ATC ATG GCG 
AAC CTT GGC TAC TGG-3’  
- 3’Fse-MoPrP: 5’-CGC TCA CAA TCG CGG CCG GCC TCA TCC CAC GAT 
CAG GAA GAT GAG G-3’ 
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The PCR products were then inserted into pJB1 (a modified vector from 
MoPrP.Xho vector[182], in which BsiWI and FseI sites replaced the XhoI site) 
using BsiWI and FseI restriction sites. 
The PCR were performed using the Phusion DNA polymerase (New 
England Biolab) according to manufacturer’s instructions. Plasmid DNA was 
purified using the QIAprep Miniprep Kit (Qiagen). All the constructs were verified 
by sequencing. 
The pJB1 were kindly provided by the group of Prof. Glenn Telling 
(Colorado State University, USA). 
2.2 Cell culture and transfection 
Experiments with mouse cell lines were carried out in a tissue culture facility 
with strict aseptic technique. All solutions and media were pre-warmed to 37 oC 
before using.  
2.2.1 Cell lines  
N2a mouse neuroblastoma cells were purchased from the American Type 
Tissue Collection (ATCC CCL131).  
N2aPrP-/- cells [183] were kindly provided by the group of Dr. Gerold 
Schmitt-Ulms (University of Toronto, Canada). 
ScN2a cells are N2a cells that cronically infected by Rocky Mountain 
Laboratory (RML) prion strain.   
2.2.2 Cell growth  
N2a, N2aPrP-/- and ScN2a cells grew in EMEM media (Invitrogen) 
supplemented with 10 % fetal bovine serum (FBS, Gibco), 1 % non-essential amino 
acids, 1 % L-glutamax, 1 % penicillin-streptomycin. Cells were incubated at 37 oC, 
5 % CO2 in a humidified CO2 incubator. Growth medium was regularly changed 2-
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3 times weekly. When cells reached confluence they were harvested or sub-
cultured.  
Cells were harvested in cold lysis buffer (10 mM TrisHCl pH 8.0, 150 mM 
NaCl, 0.5 % Nonidet P-40 substitute, 0.5 % sodium deoxycholate). Cell debris was 
removed by centrifugation at 1000 g for 5 min in a bench microfuge (Eppendorf). 
An aliquot was taken off for quantification by BCA protein assay kit (Pierce) and 
the remaining supernatant was stored at -20 oC until use. 
2.2.3 Cell transfections 
Cell transfections were performed using X-tremeGENE 9 DNA Transfection 
Reagent (Roche) according to the manufacturer guidelines. 
Plating of the cells has been performed in a volume of 10 mL Opti-MEM 
complete medium in a 10 cm plate (Falcon) 24 hours before transfection 
(corresponding to 30 – 40 % confluency). Cells were incubated overnight. The 
DNA transfection reagent was prepared by mixing 500 µl Opti-MEM (serum-free 
medium) and 15 µl X-tremeGENE 9 DNA Transfection Reagent. Following a 5 
min incubation at RT, 5 µg plasmid DNA were added to the mixture and incubated 
for a further 30 min at RT. DNA transfection mixture was added to the cells in a 
dropwise manner. Cells were incubated with DNA transfection mixture for 18 hours 
at 37 °C, following which fresh medium was added in replacement. 
For transient transfections, 72 hours post-transfection, cell lysates were 
collected for further analysis. 
For stable transfections, 48 hours after transfection cells were splitted into 
fresh medium containing 1mg/mL Geneticin (Invitrogen). The selective medium 
was changed every 3–4 days until Geneticin-resistant foci could be identified. After 
that, the stable cell lines were maintained in medium contains 400 µg/mL Geneticin. 
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2.3 Methods for the detection of proteins  
2.3.1 SDS –polyacrylamide gel electrophoresis (SDS-PAGE)  
Samples were boiled at 100 °C for 5 min. Then samples were spun at 16,000 
x g for 1 min before loading onto 12 % Tris-Glycine gels. Gels were 
electrophoresed for 100 min at 120 V (or until the dye front ran off at the end of the 
gel). PageRuler Plus Prestained Protein Ladder (Thermo Scientific) was used as a 
molecular weight marker.  
2.3.2 Coomassie staining of gels  
After electrophoresis, gels were stained in 0.02 % Coomassie R-250 (in 50 
% methanol, 10 % acetic acid) in 1 hour with gentle agitation. Gels were de-stained 
using destaining solution (40 % methanol, 10 % acetic acid) for 2-3 hours or until 
the protein bands were visible without background staining.  
2.3.3 Western blot 
After electrophoresis, protein was transferred onto Immobilion PVDF 
membranes (Millipore) at 250 mA for 150 min or 40 V overnight by Criterion 
Blotter (Biorad). Membranes were blocked with 5 % non-fat milk powder in TBS-
T (0.05 % Tween), incubated with 1:1000 anti-PrP 3F4 antibody (Covance), anti-
PrP W226 antibody (epitope W144-N152), anti-PrP 6D11 antibody (epitope T94-
P104) or anti-PrP 12B2 antibody (epitope W88-G92) and developed by enhanced 
chemiluminescence (GE Healthcare). Band intensity was acquired using the UVI 
Soft software (UVITEC, Cambridge). 
2.4 Biochemical assays on PrPSc and PrPC  
2.4.1 Protease-K (PK) digestion 
For protease-K (PK) digestion assay, quantified protein lysates were treated 
with PK (Roche) at 37oC. ScN2a cell lysates were digested with 20 µg/mL of PK 
for 1 hour, while cell lysates from N2aPrP-/- cells were digested with 1, 2, 3 and 4 
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µg/mL of PK for 10 minutes. The reactions were stopped by adding 2 mM 
phenylmethyl-sulphonyl fluoride and the samples were centrifuged at 100,000 g for 
1 hour at 4 °C (Optima TL, Beckman Coulter, Inc.). The pellets were resuspended 
in sample buffer and used in immunoblot as described in section 2.3. For the non 
PK digested sample, 25 µg cell lysates of ScN2a were used. Total PrPC expression 
levels in N2aPrP-/- and ScN2a cell lysates were normalized on β-actin value using 
1:10,000 anti-β-actin Peroxidase (Sigma-Aldrich).  
To evaluate the role of copper in prion conversion, ScN2a cells were 
transiently transfected with pcDNA::MoPrP(1-254)WT3F4 and pcDNA::MoPrP(1-
254, H95Y)3F4 plasmids, treated for 48 hours with cuprizone (CPZ, Sigma 
Aldrich) and immediately collected for lyses, PK digestion and immunoblot as 
described above. 
2.4.2 Deglycosylation of proteins using Endo-H or PNGase-F 
For glycosidase assay, protein lysates were treated with Endo-H or PNGase-
F enzymes (New England Biolabs) according to the manufacturer instructions.  
9 μL cell lysate (1-20 µg protein) was denatured with 1 x glycoprotein 
denaturing buffer (0.5 % sodium dodecylsulfate (SDS), 1 % β-mercaptoethanol) at 
95 °C for 5 minutes. After that samples were chilled on ice and centrifuged 10 
seconds before incubation with 1500 U of Endo-H or PNGase-F in 1 x G5 or G7 
reaction buffer, 1% NP-40 at 37 oC overnight with vigorous shaking. The reaction 
was stopped by freezing at -20 oC. 
2.4.3 Solubility assay 
Cell lysates containing 50 μg of total protein was adjusted to a final volume 
of 0.5 mL in lysis buffer containing Complete Protease Inhibitors (Roche). Samples 
were incubated on ice for 20 min before being centrifuged at 100,000 g, 1 hour, 4 
°C. The supernatant was recovered and the pellet resuspended in an equal volume 
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of 5 % (wt/vol) Sarkosyl buffered with 10 mM Tris, pH 8.0. Samples were then 
methanol precipitated for further analysis by Western blot. 
2.5 Immunofluorescence  
2.5.1 Immunofluorescence for the detection of PrP and organelles  
Cells were cultured for 1 day in each well of a 24-well plate containing a 
poly-L-lysine coated coverslip and appropriate culture medium. Medium was 
removed and cells were washed with 1X PBS. Cells were fixed for 20 min in 
4% paraformaldehyde (PFA) in PBS at RT then washed twice for 15 min with 
1X PBS. Fixed cells were blocked in 10% FBS, 0.3% Triton X-100 diluted in 
PBS for 1 hour at RT. After blocking, cells were incubated at 4°C O/N with 
primary antibody in dilution buffer (1% FBS in PBS with 0.3% Triton X-100). 
Cells were washed twice with 1X PBS for 15 min. After that, cells were 
incubated for 1 hour at RT with secondary antibody conjugated with AlexaFluor 
(1:500; Invitrogen) in dilution buffer. Finally, cells were washed twice for 
15min with 1X PBS. The coverslips were taken out and dried naturally. 
Coverslips were mounted in DAPI and subsequently placed on glass slides and 
stored at 4ºC. Images were acquired with a DMIR2 confocal microscope 
equipped with Leica Confocal Software (Leica). Primary antibodies used to 
detect PrP are D18 mAb for endogenous MoPrPs, and 3F4 mAb for transfected 
MoPrPs. All organelle markers were purchased from Abcam, as were the ER 
marker (antiCalnexin), the early endosome marker (anti-EEA1), the recycling 
endosome (antiTransferrin receptor Tfn), the late endosome marker (anti-
Mannose-6 phosphate receptor M6PR) and the lysosome marker (anti-LAMP2). 
2.5.2 Surface staining  
Cells were placed on ice for 15 min then stained with Opti-MEM 
containing anti-PrP 3F4 mAb (1:1000) for 20 min. After the fixation, cells were 
washed with PBS for 3 times to remove residual fixative. Finally, cells were 
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incubated with fluorescence-conjugated secondary antibody without 
permeabilization.  
2.5.3 Endocytosis imaging  
Cells were surface-labeled on ice with anti-PrP 3F4 mAb in Opti-MEM, and 
returned to 37°C for 1 hour to induce PrP internalization. Later, cells were washed 
twice with PBS, treated with 0.5% trypsin on ice for 90 sec to remove surface 
proteins, and fixed for 20 min at RT in 4% PFA. Cells were permeabilized with 
0.2% Triton X-100 for 5 min at RT, blocked for 1 hour in 2% FBS in PBS, and 
stained with AlexaFluor-488 anti-mouse antibody for 1 hour. Finally, coverslips 
were washed with PBS for 3-4 times and mounted on glass [184]. 
2.6 X-ray Absorption measurements 
Note: All X-ray absorption measurements were performed by the group of 
Prof. Paola D’Angelo (Department of Chemistry, University of Rome “La 
Sapienza”, Rome, Italy).  
2.6.1 Sample preparation 
Refolded proteins were concentrated to 1.5-2 mM using Amicon centrifugal 
cells (Millipore). Samples with 1:1 Cu(II):WT and mutants HuPrP(90-231) ratio 
were prepared in 25 mM NaOAc pH 5.5 and 25 mM MOPS buffer pH 7.0. The 
Cu(I):WT and mutants HuPrP(90-231) complexes were generated reducing Cu(II) 
with 40 mM ascorbate. 
2.6.2 X-ray absorption experiments 
X-ray absorption spectra were recorded at the European Synchrotron 
Radiation Facility (ESRF) on beam line BM30B FAME35, under ring conditions 
of 6.0 GeV and 180 mA. All the spectra were collected at 15 K. The spectra were 
collected at the Cu K-edges in fluorescence mode using a solid state 30-element Ge 
detector, with sample orientation at 45° to incident beam. The X-ray photon beam 
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was vertically focused by a Ni−Pt mirror, and dynamically sagittally focused in the 
horizontal size. The monochromator was equipped with a Si(111) double crystal, in 
which the second crystal was elastically bent to a cylindrical cross section. The 
energy resolution at the Cu K-edge is 0.5 eV. The spectra were calibrated by 
assigning the first inflection point of the Cu foil spectrum to 8981. All the spectra 
were collected at 10 K. For the Cu(II) samples photo reduction was observed and 
thus the beam was moved to different spots of the sample at each scan. During 
collection, data were continuously monitored in order to insure sample homogenity 
across the multiple spots and cells. Complete data sets were collected for samples 
1 to 14. For each sample, 12 spectra were recorded with a 7 s/point collection 
statistic and averaged. The collection time was 25 min for each spectrum. 
2.6.3 EXAFS data analysis 
EXAFS data analysis was performed using the GNXAS code, which is based 
on the decomposition of the EXAFS signal (defined as the oscillation with respect 
to the atomic background cross-section normalized to the corresponding K-edge 
channel cross-section) into a summation over n-body distribution functions γ(n), 
calculated by means of the multiple-scattering (MS) theory36. The analysis of the 
EXAFS spectra was carried out starting from the coordination model previously 
determined30. In particular, Cu(II) was found to be coordinated to H95, H110, and 
two additional low Z ligands (oxygen or nitrogen donors) in the inner shell and to 
a sulphur-donating ligand, which was assigned to M108. The final fit included also 
one close oxygen-donating ligand that was assumed to derive from solvent, 
although it could also be derived from a protein ligand such as a Q97. Based on this 
model, theoretical EXAFS spectra were calculated to include contributions from 
first shell two-body signals, and three-atom configurations associated with the His 
rings. The model χ(k) signal has been then refined against the experimental data by 
using a least-squares minimization procedure in which structural and nonstructural 
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parameters are allowed to float. The structural parameters are bond distance (R) and 
bond variance (σ2R) for a two-body signal, the two shorter bond distances, the 
intervening angle (θ), and the six covariance matrix elements for a three-body 
signal. During the minimization procedures, the magnitudes of the Debye−Waller 
terms for the imidazole rings were assumed to increase with distance, and imidazole 
ring atoms at similar distances from the copper ion were assigned the same value. 
The EXAFS spectra of Cu(II)-HuPrP(90-231, H95Y or P101L or Q211P) and 
Cu(I)-HuPrP(90-231, H95Y or P101L or Q211P) were analyzed trying out different 
possible models including either one or two histidine ligands and a sulfur 
coordinating atom. In all cases two additional nonstructural parameters were 
minimized, namely E0 (core ionization threshold) and S02 (many body amplitude 
reduction factor). The quality of the fits was determined by the goodness-of-fit 
parameters, Ri [185], and by careful inspection of the EXAFS residuals and their 
Fourier Transforms. 
2.7 Preparation of PrPSc or PrPres seed by sodium phosphotungstic acid 
(PTA) 
1 mg of ScN2a or N2aPrP-/- cell lysate was used for PTA precipitation by 
adding 500 μL of PBS containing 4 % sarkosyl, complete protease inhibitor (Roche) 
and 0.5 % PTA, with constant shaking 350 rpm, at 37 °C for 1 hour and centrifuged 
14,000 g for 30 min at RT. The pellet was washed with 500 μL of PBS/2% 
Sarkosyl/protease inhibitor and then centrifuged the pellet again at 14,000 × g for 
30 min at RT. After that, the pellet was resuspended in 150 μL of sterile distilled 
water and stored at −80 °C until use. 
2.8 Protein misfolding cyclic amplification (PMCA) 
Brains from wild type mice were harvested after perfusion, and 10 % 
homogenate was prepared in conversion buffer (1 % Triton-X100, 5 mM EDTA, 
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and 150 mM NaCl in PBS pH 7.2) with the addition of Complete Protease Inhibitors 
(Roche), divided in single-experiment aliquots and keep at –80 ºC. 
Sample were mixed with substrate and subjected to 96 cycles of PMCA with 
the use of a microsonicator (model Q700, Qsonica). Each cycle consisted of 29 
minutes 30 seconds of incubation at 37 °C, followed by a 30-second pulse of 
sonication set at a potency of 250 W. After one round, an aliquot of the amplified 
material was diluted 1:10 into fresh brain homogenate, mixed well and performed 
an additional round of PMCA cycles.  
Amplified samples were treated with 100 μg/mL proteinase K at 37 °C for 1 
hour with shaking. The reaction was stopped by SDS-PAGE sample buffer, and 
samples were loaded into SDS-PAGE followed by immunobloting as previously 
described in section 2.3. 
2.9 Preparation of recombinant proteins  
2.9.1 Protein expression  
All recombinant MoPrP and HuPrP variants in this study were expressed and 
produced in LB medium (10 g trypton, 5 g yeast extract, 10 g NaCl) according to 
the following protocol: freshly transformed 100 mL overnight culture of E. coli 
BL21 (DE3) cells was added to 2 L of LB medium plus ampicillin (100 µg/mL) in 
a Biostat B plus 2 L bioreactor (Sartorius) which allows for an automated control 
of pH, temperature and pO2. The expression was induced at 0.8 OD600 with 1 mM 
IPTG. The cells were harvested 12 hours after induction by centrifugation at 4000 
g, 4 °C for 30 min.  
2.9.2 Isolation of inclusion bodies 
Bacteria pellet was resuspended in 25 mM Tris-HCl, 5 mM EDTA, 0.8 % 
TritonX-100, 0.4 % Deoxycholic acid, 1 mM PMSF, pH 8 and lysed by Panda plus 
homogenizer at 4 oC.  Bacteria cells were disrupted by three cycles of mechanical 
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lysis at 1500 bar. Inclusion bodies (IBs) were collect by centrifugation at 10,000 g, 
30 min, 4 °C, washed one time with washing buffer (25 mM Tris-HCl, 5 mM 
EDTA, 0.8 % Triton-X100, pH 8), and then with cold water two times. Washed IBs 
were solubilized in 5 volumes of 8 M GndHCl, and then removed bacterial debris 
by centrifugation at 10,000 g, 30 min, 4 °C. 
2.9.3 Protein purification 
The dissolved IBs in 8 M GndHCl were diluted to 6 M GndHCl using 50 
mM Tris, 1 M NaCl, pH 8.0 then loaded onto a 5 mL HisTrap crude column (GE 
Healthcare) in binding buffer (2 M GndHCl, 500 mM NaCl, 20 mM Tris, 20 mM 
imidazole, pH 8.0). After that, the column was washed with 3 column volume (CV) 
of binding buffer and eluted with a gradient from 0-100 % of elution buffer (5 M 
GndHCl, 500 mM NaCl, 20 mM Tris, 500 mM imidazole, pH 8.0) at 5 mL/min in 
20 min. Finally, the PrP-contained fractions were loaded onto gel filtration column 
(Superdex 200 26/60, GE) and eluted with 6 M GndHCl, 25 mM Tris-HCl, 5 mM 
EDTA, pH 8 at a flow rate of 2 mL/min. Purified protein was analyzed by SDS-
PAGE. Protein concentration was determined by UV at 280 nm and stored at −80 
°C before use.  
2.9.4 Protein refolding 
Purified prion proteins were rapidly diluted to a final concentration of 0.1 
mg/mL using 25 mM Tris, 5 mM EDTA, pH 8.0. Then the samples were dialyzed 
against refolding buffer (20 mM NaOAc, 0.005% NaN3, pH 5.5) using a 3 kDa 
molecular weight cut-off (MWCO) membrane (Spectra/Por), until a final GndHCl 
concentration of about 10 µM. 
2.10 Monitoring the kinetics of in vitro amyloid formation 
To monitor the formation of amyloid fibrils in our samples, we use a protocol 
adapted from Colby et al. [186]. The refolded prion protein was prepared to 2X 
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stock solution by dilution buffer (4 M GndHCl in PBS pH 7.0) to concentration of 
200 μg/mL protein and 2 M GndHCl. Then stock solution was dilution two times 
in PBS pH 7.0, 2 M GndHCl, 20 μM ThT. For seeding experiments, 4 μL 
resuspended PTA pellet was diluted into 400 μL of water and 20 μL of the diluted 
sample was added to each well.   
The fibrillization reaction was performed in a final volume of 200 μL in 96-
well plate (BD Falcon) and each well was added one 3-mm glass bead (Sigma-
Aldrich) for increasing agitation. The plate was continuous shaking at 37 oC on a 
plate reader (Spectramax M5, Molecular Device). The kinetics of fibril formation 
was monitored by reading fluorescence intensity every 10 min at 444 nm excitation 
and 485 nm emission. The lag phase was estimated based on 10 % of the ThT 
fluorescence increasing. 
2.11 Generation and detection of transgenic mice 
MoPrP mutant transgenes (H95Y or H95.110Y) containing mouse 
regulatory sequences were excised from the plasmid pJB::MoPrP(1-254, H95Y) by 
using the restriction endonuclease NotI. These fragments were then microinjected 
into the pronucleus of 200 fertilized FVB mice eggs, which were implanted into 
pseudopregnant FVB females. This work was done at the transgenic mouse facility 
of Cyagen Biosciences Inc (USA).  
DNA was prepared from tail of F0 offspring mice was used to screen for 
transgene integration by a PCR assay using specific primers. The primers used were 
5′-GAA CTG AAC CAT TTC AAC CGA G-3′ and 5′-AGA GCT ACA GGT GGA 
TAA CC-3′. The presence of PCR-amplified products of 800 bp indicated the 
presence of MoPrP mutant transgenes. Transgenic F0 mice were crossed with WT 
mice to obtain an F1 generation that was also screened using PCR amplification as 
above. Homozygous transgenic lines were established in two steps. Founders were 
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backcrossed to homozygous null animals MoPrP-/- (Prnp-/-) to obtain homozygosity 
for the null mutation. Interbreeding within the same transgenic line yielded 
homozygosity for the MoPrP mutant constructs. These work with transgenic mice 
were performed in collaboration with the group of Prof. Juan-María Torres at 
Centro de Investigación en Sanidad Animal (CISA-INIA), Madrid, Spain. 
2.12 PK immunoblot analysis of mouse brain homogenates  
10 % (wt/vol) brain homogenates from frozen tissues were prepared in lysis 
buffer (100 mM sodium chloride, 10 mM EDTA, 0.5 % Nonidet P40, 0.5 % sodium 
deoxycholate in 10 mM Tris-HCl, pH 7.4). Aliquots of cleared lysate equivalent to 
100 µg were digested with 50 µg/mL of PK for 1 hour at 37 °C. Reactions were 
terminated by the addition of phenylmethanesulfonyl fluoride (PMSF, 5 mM). 
Treated homogenates were analysed by immunoblot using anti-PrP 12B2 antibody. 
2.13 Cell viability 
Cells were seeded in a 96-well tissue culture plate one day before transfection 
and then transiently transfected with MoPrP constructs. Seventy-two hours after the 
transfection, the medium was removed and the cells were incubated with 200 μL of 
MTT (Sigma) working solution (5 mg/mL of MTT in sterile PBS) for 4 hours at 37 
°C. Cell viability was assessed by the conversion of MTT (yellow) to a formazan 
product (purple). The solution was removed and formazan products were dissolved 
by adding 200 μL of DMSO to each well. The optical density was read at 570 nm 
and the background subtracted at 690 nm using a VersaMax plate reader (Molecular 
Device). Each assay was performed in duplication of 4 wells. 
2.14 Statistical analysis  
Data were expressed as mean plus standard error of mean (SEM; sd√n). Data 
were compared by 2-tailed t-tests and considered significantly different when 
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P<0.05. Degree of significance was expressed as follows: P<0.05*; P<0.01**; 
P<0.001***, unless otherwise specified. 
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CHAPTER III 
RESULTS 
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3.1 Role of fifth copper binding site in prion conversion 
3.1.1 The non-OR H95Y mutation promotes prion conversion 
Expression of exogenous PrP in a prion-infected mouse neuroblastoma 
(ScN2a) cell results in its conversion to PrPSc, so it is a useful tool to study prion 
conversion. In this study, we engineered the MoPrP constructs to include the 
human-specific 3F4 epitope (Met substitutions at residues 108 and 111), known not 
to interfere with the conversion process (Figure S1) and allow distinguishing 
exogenous MoPrP from endogenous MoPrP [103, 187, 188]. To investigate the role 
of copper binding sites of prion protein, we created MoPrP mutants in which single 
His residues along the entire N-terminal domain were replaced by Tyr (denoted as 
H60Y, H68Y, H76Y, H84Y and H95Y mutations). The His residue 110 was not 
considered in this experiment because it is located inside the 3F4 epitope, so 
replacing His110 would destroy the epitope and the anti-PrP 3F4 mAb cannot 
recognize mutants (Figure S3).   
The substitution of histidine by tyrosine in MoPrP constructs were not toxic 
for cells (Figure S2) and also did not affect PrP expression as all constructs shared 
a similar PrP expression level (Figure 13). Meanwhile the PK-resistant profiles 
displayed interesting results. When a histidine in the OR was replaced by tyrosine, 
it had no significant effect on prion conversion, and all OR mutants (H60Y, H68Y, 
H76Y, H84Y) displayed the same PK-resistant PrPSc levels as WT. Conversely, the 
non-OR mutant (H95Y) yielded in significantly higher PrPSc, around 3 times more 
than the others (Figure 13), providing the first evidence for the role of this mutation 
in prion replication.  
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Figure 13. The non-OR H95Y mutation promotes prion conversion. (A) For 
non-PK experiment, 50 μg of undigested lysates was applied to each lane; β-actin 
was used as internal control. For PK experiment, 500 μg of cell lysate was digested 
with PK (20 μg/mL) at 37°C for 1 hour. PrPs were detected by anti-PrP 3F4 mAb. 
(C) Quantitative analysis of PK-resistance levels (PrPSc) in transfected constructs. 
(n = 4, ***p< 0.001). 
3.1.2 Cuprizone removal of copper increased level of PrPSc in MoPrP WT but 
not in H95Y 
Because H95 binds copper, it is likely that the removal of this copper ligand 
might accelerate prion replication in ScN2a cells. Therefore, the absence of copper 
from the non-OR region could promote this pathological process. To verify this 
hypothesis, we treated ScN2a cells transfected either with WT or H95Y with 
cuprizone (CPZ), a well-known selective Cu(II) chelator that does not affect cell 
viability and cannot cross plasma membranes [189]. After 48 hours of CPZ 
treatment, PK-resistance levels were evaluated. 
CPZ treatments on WT ScN2a cells promoted a significant increase in PrPSc-
PK resistance levels upon 10µM CPZ additions, suggesting that PrPC in the apo 
form is more susceptible to PrPSc conversion (Figure 14). The PrPSc levels remained 
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a plateau among control and CPZ-treated H95Y ScN2a cells but always higher than 
PrPSc level in the WT cells as presented previously. These data were consistent with 
the hypothesized mechanism whereby H95Y mutant was per se sufficient to 
generate high amount of PrPSc molecules. Copper appeared as a pivotal modulator 
of this process since its absence from PrPC seemed to promote prion conversion. 
 
Figure 14. Cuprizone removal of copper increased level of PrPSc in MoPrP WT 
but not in H95Y. (A) After transfection, ScN2a cells were treated for 48 hours 
with cuprizone (CPZ) and collected for PK digestion assay. For non-PK 
experiment, 50 μg of undigested lysates was applied to each lane. For PK 
experiment, 500 μg of cell lysates was digested with PK (20 μg/mL) at 37°C for 1 
hour. MoPrPs were detected by anti-PrP 3F4 antibody. (B) Quantitative analysis of 
PrPSc PK-resistance levels in WT and H95Y MoPrP transfected ScN2a cells treated 
with 10 μM CPZ (n = 3, *P< 0.05, n.s: non-significant) 
3.1.3 Localization and trafficking of H95Y mutant in N2a cell 
PrP WT and H95Y mutant were expressed in N2a cells and selectively 
visualized by immunofluoresence with the 3F4 mAb. The 3F4-tagged WT and 
H95Y PrPs were found predominantly on the cell surface, with some intracellular 
punctated deposits in perinuclear region. The distribution of WT and mutant PrPs 
found in this study is similar to previous reports [190, 191] (Figure 15).  
63 
 
 
Figure 15. H95Y mutant is predominantly expressed on cell surface as wild-
type PrPC. (A) Cell surface staining. PrPs on cell surface were detected by anti-
PrP 3F4 mAb without permeabilization. (B) Combined cell surface and 
intracellular staining. PrPs were detected by anti-PrP 3F4 mAb with 
permeabilization. Insets represent magnifications of some cells in the merge 
images. Blue fluorescence for nucleus, green fluorescence for PrP. Scale bars: 24 
µm. 
PrPC is trafficked through the secretory pathway to the cell surface, but not 
all PrPC remain on the cell surface after their delivery there. PrPC has been 
demonstrated that it is rapidly and constitutively endocytosed by the endosomal 
system [40] and copper has been previously implicated in the endocytic trafficking 
of PrPC [137, 192]. Therefore, we investigated whether the alteration of copper 
binding of PrP by removing H95 may have an effect on the endocytosis. For this 
purpose, cells were surface-labeled on ice with anti-PrP 3F4 mAb and returned to 
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37 °C to induce PrP internalization. After that the extracellular PrPC were removed 
by trypsin, so only endocytosed PrPs were detected. We observed that both PrP 
WT and H95Y exhibited intracellular fluorescence signals corresponding to 
endocytosed PrPs, indicating that H95Y was efficiently efficiently endocytosed as 
WT (Figure 16). We concluded that replacing of histidine by tyrosine at His95 do 
not impair PrPC internalization from cell surface.  
 
Figure 16. Substitution of histidine by tyrosine at H95 does not impair PrP 
endocytosis. Cells were surface-labeled on ice with anti-PrP 3F4 mAb and 
returned to 37 °C to induce PrP internalization. Only endocytosed PrPs were 
detected after removing surface proteins by trypsin. Insets show magnifications of 
cells in the merge images. Blue fluorescence for nucleus, green fluorescence for 
PrP. Scale bars: 24 µm.  
To further investigate the sub-cellular localization and trafficking of PrPC, 
we analyzed the localization patterns of 3F4-tagged WT and H95Y mutant with 
some organelle markers. The results showed that most PrPC WT is found on cell 
surface, while there is a small portion in the endosomes and lysosomes (Figure 
17A). These results are consistent with those obtained from previous studies that 
analyzed the localization of WT PrPC in different cell lines [193, 194]. In cells 
expressing the H95Y mutant, PrPC is still mainly expressed on cell surface. In 
addition, a smaller fraction of H95Y mutant was found in the late endosomes and 
lysosomes as PrP WT. However, a significant population of intracellular H95Y 
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mutant showed co-localization with EEA1 (an early endosome marker) and Tfn (a 
recycling endosome marker), suggesting an accumulation of H95Y mutant in early 
and recycling endosomes (Figure 17B). 
 
Figure 17. The H95Y mutant displays intracellular accumulation in early and 
recycling endosomes. PrP localization in N2a cells expressing the MoPrP WT (A) 
or the MoPrP H95Y (B). Nuclei are labeled with DAPI (blue), PrPs are detected 
by 3F4 antibody (green), while organelle markers, as Calnexin (ER marker), EEA1 
66 
 
(early endosomes marker), Tfn (recycling endosomes marker), M6PR (late 
endosomes marker) and LAMP2 (lysosomes marker), are labeled in red. Insets 
show a magnification of the merged panels (white boxed areas). Scale bars: 12 
µm.  
Endosomal compartments have been known as acidic compartments [195-
197]. This acidic pH has been suggested as a critical condition for changes in PrP 
conformation [198]. Previous studies have shown that the transition of PrP from its 
native state to soluble oligomers is a pH-dependent process [199] and the acidic 
conditions is favor for the existence of soluble PrP oligomers [200]. Additionally, 
various studies demonstrated that PrPSc is detected throughout endosomal 
compartments, being particularly abundant in recycling endosome and the 
endosomal recycling compartment was identified as the likely site of prion 
conversion [201, 202]. Therefore, the accumulation of H95Y mutant in early and 
recycling endosomes, a proposed suitable environment for PrPSc formation might 
be an appropriate explanation for promotion effect on prion conversion of H95Y 
mutant. 
3.1.4 Effect of the H95Y mutation on the copper coordination 
In order to have more insight into the effect of H95Y mutation, we 
investigated the copper coordination in non-OR region of this mutant. High 
resolution techniques, as NMR or X-ray spectroscopy, are not able to detect any 
structural information in this region due to its intrinsic flexibility. Then we used the 
synchrotron-based X-ray absorption fine structure (XAFS) technique to study the 
coordination geometries of copper in H95Y mutant. In addition, we also analysed 
the copper binding in non-OR region of pathological mutations in the globular 
domain (Q211P, in mouse numbering) and in the N-terminal unstructured region 
(P101L, in mouse numbering). To have better comparision with these pathogenic 
mutation, truncated HuPrP(90-231) variants which are devoid of the OR were used 
in these experiments.  
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Copper coordination in the non-OR region of WT HuPrP 
At pH 5.5, EXAFS spectra of Cu(II)- and Cu(I)-HuPrP(90-231) are almost 
identical, indicating that the coordination environment of copper in HuPrP(90-231) 
is the same despite its oxidation state. Quantitative analysis of the EXAFS spectra 
indicated that in both oxidation states, copper ion is coordinated by two His residues 
(H95 and H110, in mouse numbering) with Cu-N distance of 1.98 Å, by two low Z 
ligands (either oxygen or nitrogen atoms at 1.98 Å) and by one sulphur scatterer at 
longer distance (i.e. 3.25 Å) (Figure 18). 
While at pH 5.5 the EXAFS spectra are almost identical for both copper 
oxidation states, at pH 7.0 EXAFS signals show markedly different features over 
the full k-range. The quantitative analysis of the EXAFS data indicates that at pH 
7.0 only a single His coordinates the metal ion in both oxidation states, thus 
suggesting that one of the two His residues (H95 or H110) moves away from the 
metal. EXAFS data concerning Cu(II)-HuPrP(90-231) at pH 7.0 could be modeled 
as a four coordinate copper center with one His at 1.99 Å, and three N/O scatterers 
at 1.99 Å with a more distant sulphur scatterers at 3.47 Å. As far as the Cu(I)-
HuPrP(90-231) protein is concerned, the EXAFS analysis revealed a three-fold 
coordination with one His at 1.98 Å, one N/O scatterers at 2.00 Å and one sulphur 
scatterer at 2.27 Å (Figure 18). 
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Figure 18. Copper coordination in the non-OR region of HuPrP WT. (A) k3-
weighted EXAFS spectra and Fourier transforms of the experimental data of 
Cu(II) and Cu(I) bound to HuPrP(90-231) WT at pH 5.5 and 7.0. (B) Schematic 
representations of copper binding sites in HuPrP(90-231) WT 
Copper coordination in H95Y mutant  
At pH 5.5, the Cu K-edge EXAFS data for H95Y, compared to the WT 
protein, exhibited a clear modification in the coordination environment. This 
variation is explained by the existence of a single His in the non-OR region of the 
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H95Y mutant, hampering the coordination of the Cu(II) ion with two His residues 
(Figure 19). Conversely, at pH 7.0 the EXAFS spectra of the H95Y mutant and WT 
proteins are almost identical, thus suggesting that H110 is involved in the copper 
binding site in both cases. In addition, the EXAFS data showed that the H95Y 
mutant maintains the same coordination environment around the Cu(II) ion when 
increasing pH from 5.5 to 7.0. The analysis of the EXAFS data revealed the 
presence of a four coordinate copper center almost identical to that of the WT 
protein at pH 7.0, with the H110 residue at 2.00 Å from the ion. In sum, the copper 
coordination of H95Y mutant is independently of the pH and similar to copper 
coordination of WT at pH 7.0. Interestingly, the pathogenic mutants, HuPrP Q211P 
and P101L, shared the same coordination pattern as H95Y mutants at both pH 5.5 
and 7.0 (Figure S4). 
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Figure 19. Copper coordination in the non-OR region of HuPrP H95Y. (A) 
k3-weighted EXAFS spectra and Fourier transforms of the experimental data of 
Cu(II) bound to HuPrP(90-231) WT and H95Y at pH 5.5 and 7.0. (B) Schematic 
representations of copper binding sites in HuPrP(90-231) H95Y.  
3.1.5 Amino acid scanning reveals H95 as a “hot spot” for prion conversion   
In order to investigate further the potential role of the fifth copper-binding 
site in prion conversion, we created the amino acid scanning at H95, in which all 
possible amino acid substitutions were introduced. Then the influence of this 
substitution on the conversion efficiency was evaluated based on PK-digestion 
assay in ScN2a cells. 
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Western blot analysis of ScN2a cells transfected with H95X (where X means 
any amino acids) mutants revealed a very interesting result. The expression level of 
H95X mutants was almost equal to that of WT, but the PK-resistant level showed 
large variation. When H95 was replaced by neutral or small amino acid (A, G, C, 
S, T, N, Q, P), the PrPSc level was almost similar to WT. Remarkably, in the case 
of hydrophobic amino acid substitutions (F, Y, L, M, V, W, I), the prion conversion 
was highly promoted featuring high PrPSc level in ScN2a cells when transfected 
with these mutants. In some case, such as F, V, I, the PrPSc level were 2-3 times 
higher than WT. Meanwhile, only a small amount of PrPSc was detected in the 
mutants with charged amino acid residues (D, E, R, K) at H95, suggesting that prion 
replication was inhibited by the presence of these mutations at codon 95. These data 
showed that the hydrophobicity of amino acid at H95 might have an impact on 
PrPC-PrPSc conversion. Therefore, the fifth copper-binding site represents a “hot 
spot” for prion conversion, because by changing the amino acid at this position, the 
prion conversion process could be promoted or inhibited.  
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Figure 20. Effects of amino acid substitutions at His95 to prion conversion 
process. (A) For non-PK experiment, 50 μg of undigested lysate was applied to 
each lane, β-actin was used as internal control. For PK experiment, 500 μg of cell 
lysates was digested with PK (20 μg/mL) at 37°C for 1 hour. PrPs were detected by 
anti-PrP 3F4 mAb. (C) Quantitative analysis of PK-resistance levels (PrPSc) in 
transfected constructs.  
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3.2 Non-OR mutants induce de novo generation of prions in vitro  
3.2.1 Generation of stable N2aPrP-/- cells expressing PrP WT and non-OR 
mutants  
As mentioned before, when replacing histidine by tyrosine at Histidine 110 
residues, we altered the 3F4 epitope (Figure S3), therefore we could not use the 
ScN2a cells system for experiments with mutations at H110. In addition, to avoid 
any possible influence of endogenous PrPC on the de novo generation of prions, we 
used the N2aPrP-/- cells that did not express PrP (Figure 21), that were subsequently 
stably transfected with WT or non-OR mutants PrPs. Plasmids pcDNA::MoPrP(1-
254), pcDNA::MoPrP(1-254, H95Y), pcDNA::MoPrP(1-254, H110Y) and 
pcDNA::MoPrP(1-254, H95Y/H110Y) were used for transfection of N2aPrP-/- 
cells. Following selection, we obtained Geneticin-resistant N2aPrP-/- cells 
indicating the integration of plasmid DNA into genomic DNA so selected cells had 
the ability to constitutively express the PrP gene. To determine whether PrPC was 
stably expressed at the protein level, western blot was performed. The clones which 
had positive signal were selected and designated N2aPrP-/--WT, N2aPrP-/--H95Y, 
N2aPrP-/--H110Y and N2aPrP-/--H95Y/H110Y (Figure 21). 
 
Figure 21. Expression of PrPC in N2aPrP-/- constructs. Fifty μg of cell lysate 
was applied to each lane. PrPs were detected with anti-PrP W226 mAb.  
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3.2.2 The non-OR mutants share similar glycosylation patterns and 
proteolytic features as WT PrPC 
PrPC is synthesized in the endoplasmic reticulum (ER). During biogenesis, 
PrPC is co-translationally directed into the secretory pathway to reach the cell 
surface. The maturation of PrPC is achieved by the attachment of two N-linked 
complex carbohydrate moieties, the disulfide bond formation and the addition of a 
GPI anchor at its C-terminus. To elucidate whether the mutants could alter cellular 
maturation processes, we analysed the glycosylation patterns and proteolytic 
features of PrP mutants. 
First, the expression of PrPC was analysed by immunoblot (Figure 22A), 
which demonstrated that, like WT, the H95Y, H110Y and H95Y/H110Y mutant 
PrPC had similar glycosylation patterns with three bands corresponding to the 
diglycosylated, monoglycosylated and unglycosylated PrPC forms. This result 
indicated that non-OR mutations PrPs did not affect the glycosylation of PrPC. 
After that, we performed the deglycosylation assays using Endo-H and 
PNGase-F. Endo-H is a highly specific endoglycosidase, which cleaves asparagine-
linked mannose rich oligosaccharides, but not highly processed complex 
oligosaccharides from glycoproteins. Therefore, Endo-H is used to monitor 
posttranslational modification in the Golgi apparatus. Because glycoproteins 
acquire Endo-H resistance upon transport to the Golgi compartments, Endo-H 
sensitivity is considered a sign of protein immaturity [203]. Meanwhile, PNGase-F 
is able to remove most N-glycans and used to detect glycoproteins. 
Immunoblotting of all MoPrP constructs treated with Endo-H showed no 
difference between WT and mutated PrP glycoforms (Figure 22C). The treatments 
with the PNGase-F also displayed the same patterns between constructs with a 
clearly band at molecular weight of about 25 kDa, which was identical to 
unglycosylated PrPC (Figure 17B). Meanwhile, bands with higher molecular weight 
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(35-45 kDa) corresponding to mono and diglycosylated PrPC were undetected. 
Taken together, these data suggested that these mutant proteins were successfully 
processed through ER and Golgi compartments during their maturation.  
 
Figure 22. The non-OR mutations share the same glycosylation patterns and 
proteolytic characteristics as PrP WT. (A) 50 μg of cell lysate was applied to 
each lane. (B) Lysates were either digested with PNGase F or (C) Endo H. PrPs 
were detected with anti-PrP W226 mAb. The positions of diglycosylated, 
monoglycosylated and unglycosylated forms of PrPC and the C-terminal fragment 
(C1) are on the right of blot. 
In the PNGase assay, the immunoblot also showed an additional band of 
about 15 kDa (Figure 22B), corresponding to the major C-terminal fragment of PrPC 
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(C1 fragment). Similar to many other cell surface proteins, PrPC can be 
differentially cleaved at specific sites to generate various fragments. In normal 
tissues and cells, PrPC is mainly cleaved at the 110/111 or 111/112 peptide bonds 
(termed α-cleavage), yielding the C-terminal fragment (C1) tethered to the plasma 
membrane and releasing the corresponding N-terminal fragment (N1) [204-206]. 
Although in H110Y and H95Y/H110Y mutants, H110 at cleavage site was replaced 
by Tyr, C1 fragment has been still detected. This suggested that the substitution of 
histidine by tyrosine at H110 did not affect the α-cleavage process. 
3.2.3 The non-OR mutants do not alter the solubility and protease resistant 
profile of PrPC 
PrPSc can be distinguished from PrPC by several biochemical properties, of 
which detergent insoluble and protease resistance stand out as the most prominent 
[207, 208]. Here we examined the PrPC mutants to test whether the His-to-Tyr 
substitution could alter these features of PrPC. 
To investigate solubility, cell lysates were extracted in lysis buffer and 
centrifuged at high speed. Subsequently, the pellets and supernatants were tested 
for the presence of PrPs. The insolubility of PrP mutants slightly increases 
compared to WT, but this difference was not statistically significant. In N2aPrP-/- 
WT, almost all PrPC was found in the supernatant fraction while only 4% was in 
the pellet. Similarly, less than 7% of PrP was detected in the insoluble fraction of 
non-OR mutants (Figure 23). 
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Figure 23. Solubility of PrP is slightly decreased in non-OR mutants. (A) 
N2aPrP-/- cells stably expressed WT and non-OR mutants. Supernatant (S) and 
pellet (P) fractions from cell lysates were collected following 100,000 × g 
centrifugation. PrPs were detected by anti-PrP W226 mAb. (B) Solubility profile 
of each PrP, determined by the relative densitometry of the pellet signal relative to 
the total of pellet and supernatant signal. 
Similarly, when examining the sensitivity of non-OR mutants to protease 
digestion, we found that PrP mutants were rapidly digested by PK, just as WT was. 
In this experiment, PrPs were treated with increased concentrations of PK and the 
reaction was performed at 37oC in 10 min in order to better monitor PK-resistance 
levels. The single mutations (H95Y, H110Y) shared almost the same PK-resistance 
profile with WT; while the double mutations (H95Y/110Y) had slightly higher PK-
resistance levels yet statistically not significant (Figure 24). 
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Figure 24. The WT PrPC and non-OR mutants displayed similar PK-resistance 
profile when expressed in N2aPrP-/- cells.  N2aPrP-/- cells stably expressed WT 
and non-OR mutants. (A) 100 µg cell lysates were treated with 1 to 4 µg/mL of PK 
at 37oC for 10 min, 25 µg of undigested cell lysate was loaded in the case of the 
untreated sample. PrPs were detected by anti-PrP W226 mAb. (B) PK resistant 
profile of each PrP, determined by the relative densitometry of the treated sample 
relative to the untreated sample signal. 
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3.2.4 Substitution of Histidine by Tyrosine at non-OR copper-binding site 
accelerates fibrillization process 
In order to study the impacts of His-to-Tyr replacement in the non-OR region 
on fibril formation, recMoPrP mutants were produced and applied to fibrillization 
assays. Experiments were performed at pH 7.0 in the presence of 2M GndHCl. We 
used this chaotropic agent at this concentration was demonstrated to facilitate 
aggregation efficiency [209]. The kinetics of filbrillization were monitored by 
measuring changes in Thioflavin T (ThT) fluorescence intensity. This dye show 
strong increase of fluorescence upon binding to β-sheet rich structures like amyloid 
aggregates, hence is used as a marker for newly generated amyloid structural 
motives [210].  
The typical sigmoidal curves of amyloid formation were obtained for both 
recMoPrP WT and recMoPrP mutants (Figure 25). All mutants formed fibrils faster 
than the recMoPrP WT as indicated by their shorter lag phases. In unseeded 
experiments (Figure 25 A, B), the fibrillization reaction of recMoPrP WT showed 
the longest lag phase (48 ± 7.3 hours). The single mutations, H95Y and H110Y, 
shared similar kinetic profiles with a shorter lag phase than WT, indicating that both 
mutations can significantly promotes protein fibrillization. Then, when replacing 
both His by Tyr, the double mutation H95Y/H110Y displayed the shortest lag phase 
(23.4 ± 3.7 hours) as a result of the cumulative effect. Similar results were also 
noted in the seeded experiments. In these experiments, PrPSc seeds purified using 
phosphotungstate (PTA) precipitation [186] were added into the reactions and the 
seeding effect was clearly observed in all cases. In the presence of PrPSc seed, 
recMoPrP H95Y/H110Y was rapidly converted to amyloid fibrils with only 10 
hours of lag phase. The single mutations needed around 13 hours before ThT 
fluorescence intensity started to increase. Meanwhile PrPSc seed reduced the lag 
phase of recMoPrP WT to 20 hours. In sum, non-OR mutants had higher intrinsic 
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amyloidogenic potential as compared to MoPrP WT, of which the double mutant 
H95Y/H110Y had highest fibrillization propensity. 
 
 Figure 25. recMoPrP non-OR mutants dramatically promote polymerization 
processes. recMoPrP WT (WT), recMoPrP H95Y (H95Y), recMoPrP H110Y 
(H110Y), recMoPrP H95Y/H110Y (H95Y/H110Y) were adding into fibrillization 
reactions. The kinetics of MoPrP fibrillization with (C) or without (A) PrPSc seeds 
at pH 7.0, 2 M GndHCl. Mean value of lag phase in the presence (D) or absence 
(B) of PrPSc seeds were determined and compared. (n = 4, *p<0.05, **p<0.01, 
***p<0.001).  
 
3.2.5 Non-OR mutants-derived seeds accelerates PrP polymerization in the 
amyloid seeding assay 
Although, non-OR mutants expressed in N2aPrP-/- did not present similar 
characteristics of PrPSc, the results from the fibrillization assays showed that they 
had high fibrillization propensity and form fibrils faster than the WT PrP. 
Furthermore, H95Y mutant expressed in ScN2a cell also accelerated the prion 
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conversion. On the basis of these results, we reasoned whether the non-OR mutants 
expressed in N2aPrP-/- cells might spontaneously convert and behave as an 
infectious prion. To test this hypothesis, we examined the amyloid seeding assay 
(ASA), a method that is able to detect PrPSc (both PK sensitive and resistant) from 
different human or animal infected brain samples [186, 211].   
Non-OR mutant “seeds” were isolated from N2aPrP-/--H95Y, N2aPrP-/--
H110Y, N2aPrP-/--H95Y/H110Y cell lysates by PTA precipitation, and seeds from 
N2aPrP-/--WT cells were also isolated and used as a control. After that, seeds were 
added into the reactions containing recMoPrP WT as substrate, 2 M GdnHCl, pH 
7.0 under continuous shaking for 72 hours at 37 oC. In case of unseeded reactions 
used as a negative control, the lag phase of the fibrillization process took around 50 
hours. When scrapie seeds were added to the reactions, the amyloid formed much 
more rapidly, resulting in the reduction of the lag phase to 20 hours. Interestingly, 
non-OR mutants-derived seeds also showed seeding activity. All three mutants, 
H95Y, H110Y, H95Y/H110Y had the same effects. Seeds derived from these 
mutants accelerated the formation of amyloid. The lag phases for these reactions 
were about 35 hours, corresponding to a 30% reduction compared to unseeded 
reactions. Surprisingly, the lag phase for H95Y/H110Y-seeded reaction was the 
same as the lag phase for H95Y or H110Y-seeded reactions although results from 
the above fibrillization assay showed H95Y/H110Y had higher fibrillization 
propensity and could form amyloid faster than H95Y or H110Y. On the other hand, 
seeds prepared from N2aPrP-/--WT cells did not show any significant change in the 
lag phase: these reactions still had a lag phase of 50 hours, similar to the unseeded 
reactions.       
82 
 
 
Figure 26. Non-OR mutants-derived seeds accelerates PrP polymerization. (A) 
The kinetics of MoPrP fibrillization in unseeded and seeded conditions. recMoPrP 
WT were adding into fibrillization reactions in 2M GndHCl, pH 7.0. Seeds were 
prepared from cell lysate of ScN2a (scrapie), N2aPrP-/- WT (WT), N2aPrP-/- H95Y 
(H95Y), N2aPrP-/- H110Y (H110Y), N2aPrP-/- H95Y/H110Y (H95Y/H110Y). (B) 
Mean values of lag phase were determined and compared. (n = 4, * p<0.05, 
***p<0.001).  
3.2.6 Spontaneous PrPres generation in N2aPrP-/- cells expressing MoPrP 
H95Y as detected by PMCA 
Protein Misfolding Cyclic amplification (PMCA) is a technique that takes 
advantage of the nucleation-dependent prion replication process to promote prion 
conversion in test tube. PMCA consists of cycles of accelerated prion replication, 
each cycle is composed of two phases. During the first phase the sample containing 
small amounts of PrPSc and an excess of PrPC are incubated to induce growing of 
PrPSc polymers. In the second phase the sample is subjected to sonication to break 
down the polymers, multiplying the number of nuclei. After each cycle, the number 
of seeds increases in an exponential fashion [212]. Thus, PMCA is able to detect 
the equivalent of a single molecule of infectious PrPSc [213]. This technique also 
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propagates prions that maintain high infectivity, strain properties and species 
specificity [213].  
In this experiment, the cell lysates from N2aPrP-/-, N2aPrP-/-WT and N2aPrP-
/-H95Y were used as samples for PMCA reactions. The substrates were prepared 
from FVB WT brain homogenates. After the first and second rounds, we could not 
detect any PrPSc in any samples. In the third round, the immunoblot of N2aPrP-/-, 
N2aPrP-/- WT samplez still showed a negative result, indicating no PrPres was 
present in these samples. Meanwhile, sample from N2aPrP-/- H95Y displayed a 
positive result. When N2aPrP-/- H95Y cell lysates were directly added to reactions, 
the PK-resistant PrPres were not detectable. However, when we concentrated 
N2aPrP-/-H95Y cell lysates by phosphotungstate (PTA) precipitation, the PrPres 
were clearly detected in this sample. This can be explained because there likely was 
only an extremely small amount of PrPres present in N2aPrP-/- H95Y cell lysates, 
which we could not detect directly using N2aPrP-/- H95Y cell lysates as sample. 
Using PTA precipitation, a method widely used to concentrate PrPSc for diagnostic 
purposes [186, 214], PrPres in N2aPrP-/- H95Y cell lysates were concentrated to the 
detectable concentration. These results were consistent with the fibrillization assay 
result, suggesting that MoPrP H95Y expressed in N2aPrP-/- cells spontaneously 
converted into PrPres, which could be detected by both ASA and PMCA.  
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Figure 27. Detection and replication of spontaneous PrPres in N2aPrP-/- 
expressing MoPrP H95Y using PMCA. 20 µL of reactions were treated with 100 
µg/mL of PK at 37 oC for 1 hour. PrPs were detected by anti-PrP 6D11 mAb. (*) 
unspecific band. 
3.3 Spontaneous generation of prion disease in Tg mice  
3.3.1 Establishment of Tg mice overexpressing MoPrP H95Y 
To establish Tg mice, we used the plasmid pJB1, a modified vector from 
MoPrP.Xho vector. This vector was demonstrated to provide relatively high levels 
of transgene-encoded polypeptides in the brains and hearts of Tg mice [182]. 
MoPrP H95Y-coding sequence was inserted into pJB1, resulting in plasmid 
pJB::MoPrP(1-254, H95Y). After that, H95Y mutant transgenes containing mouse 
regulatory sequences were excised from the plasmid pJB::MoPrP(1-254, H95Y) 
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and microinjected into the pronucleus of fertilized FVB mice eggs. Mice with 
transgene integration were screened by PCR using specific primers (Figure S8). 
Seven lines (founders) of MoPrP H95Y heterozygous Tg mice carrying the 
endogenous murine Prnp gene (Prnp+/+ H95Y+/−) were obtained. Tg lines 
H95YMoPrP-22, H95YMoPrP-40 and H95YMoPrP-51 were selected on the basis 
of their expression levels, and bred to homozygosity in a murine Prnp null 
background. To achieve this expression, selected lines were crossed with Prnp null 
mice (Prnp−/−) to achieve transgene-hemizygous lines (Prnp−/− H95Y+/−). 
Transgene expression levels were determined in brain homogenates and 
compared with PrPC levels found in FVB WT brain homogenates. Because we did 
not use 3F4 tag in this experiment, we could not discriminate transgene expression 
from endogenous expression. Therefore, PrPC expression levels in Tg mouse with 
PrPC+/+ background is included also transgene PrP H95Y and endogenous PrP WT. 
However, to facillitate the determination of transgene expression level, we use the 
brain homogenates from Tg mice with PrPC-/- background (Figure 28). Based on 
that, we found Tg lines H95YMoPrP-22, H95YMoPrP-40 and H95YMoPrP-51 
have transgene expression at ~6X, 1X and ~0.5X, respectively. MoPrP H95Y 
expressed in 22, 40 and 51 Tg lines also showed an electrophoretic profile similar 
to that of wild-type. 
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Figure 28. Immunoblots of brain extracts from Tg mice. Equivalent amounts of 
total protein were loaded into each lane. MoPrPs were detected by anti-PrP 12B2 
mAb. K22, K40, K51: represent for Tg lines H95YMoPrP-22, H95YMoPrP-40 and 
H95YMoPrP-51 in PrPC-/- background. 
3.3.2 Spontaneous disease in transgenic mice expressing MoPrP H95Y 
According to preliminary results, Tg mice expressing MoPrP H95Y (lines 
22, 51) spontaneously develop prion disease. These mice showed neurological 
clinical signs and reduced survival times compared to FVB wild-type mice (Table 
5). In Tg line 22 expressing MoPrP H95Y at high levels, Tg mice in PrP+/+ 
background (X22) were found dead at 108±19 days, while the lifespan of Tg mice 
in PrP-/- background (K22) was 96±6 days. Interestingly, disease also developed in 
H95YMoPrP-51 mice expressing low levels of MoPrP H95Y. Two Tg mice in 
PrP+/+ background (X51) were found dead at 443 and 467 days. Although the 
incubation period of these mice was longer than line 22 and only 33% (2/6) mice 
developed disease, it indicates that H95Y mutation might cause de novo prion 
diseases when expressed in Tg mice, even in low level expression.  
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Table 6. Transgene expression level and survival times of Tg mice expressing 
MoPrP H95Y 
Line 
Transgene 
expression level 
Total PrPC 
expression level 
Mean incubation 
period ± SEM (days) 
FVB WT  
(Prpn+/+) 
 1X >600 (0/6) 
X22 
(Prpn+/+ H95Y+/-) 
6X 7X 108±19 (20/20) 
K22 
(Prpn-/- H95Y+/-) 
6X 6X 96±6 (5/5) 
X40 
(Prpn+/+ H95Y+/-) 
1X 2X >350 (0/4, ongoing) 
K40 
(Prpn-/- H95Y+/-) 
1X 1X >350 (0/3, ongoing) 
X51 
(Prpn+/+ H95Y+/-) 
0.5x 1.5X 
443*, 467*, >500 (2/6, 
ongoing) 
K51 
(Prpn-/- H95Y+/-) 
0.5X 0.5X >220 (0/6, ongoing) 
The enhanced resistance to protease digestion is a primary feature to 
discriminate between PrPC and PrPSc [207, 208]. Since some Tg mice H95YMoPrP 
spontaneously developed disease, we examined the presence of PrPSc in the brains 
of these Tg mice. Brain homogenates from Tg mice showing clinical signs and 
developing disease were prepared and applied to PK digestion assay. The results 
revealed that protease-resistant PrP was observed in the brain homogenate of all Tg 
mice that developed disease (X22, K22 lines and two X51 mice) (Figure 29). These 
preliminary results are very promising, neuropathologic and histopathologic studies 
will be performed to further evaluate these Tg mice.  
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Figure 29. Western blot of brain PrPres in mice expressing MoPrP H95Y. An 
atypical sheep scrapie brain has been included as positive control, a FVB mouse 
brain as negative control. In BSE, the 12B2's epitope is cleaved by PK digestion 
process then it was also included as negative control of the 12B2 mAB. PrPs were 
detected by anti-PrP 12B2 mAb. (*) incomplete-digested band. 
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Discussion 
 
The central molecular event in prion diseases is the conversion of PrPC into 
the pathological and infectious prions termed PrPSc, whose mechanism of 
formation and transmission remains unclear in spite of numerous investigations. It 
is well established that PrPC specifically binds to copper, an essential trace metal. 
Moreover, copper seems to play an important role for PrPC stability and prion 
conversion [163, 215-219]. Nevertheless, results obtained from these studies 
showed contradiction, demanding further research to clarify the connection 
between copper and PrPSc formation.  
In this study, to investigate the copper-PrPSc relationship, we introduced the 
substitutions of Histidine by Tyrosine at N-terminal copper binding sites to abolish 
the binding of copper in these regions. Using the ScN2a cell conversion assay, we 
found that prion replication was not affected by the lack of each histidine in the 
OR. This result was in agreement with previous studies, confirming that the 
deletion of an octapeptide repeat did not lead to prion disease [165]. Moreover, PK 
treatment of PrPSc removes residues 23 to approximately 90 without loss of 
infectivity, suggesting that the OR domain does not play a role in prion conversion. 
Conversely, when we replaced His by Tyr at the non-OR region, the H95Y mutant 
strongly promoted the conversion of PrPC to PrPSc, suggesting that the non-OR 
copper binding site is much more crucial for prion propagation. Based on the fact 
that H95 has a higher copper affinity than a single OR copper binding site [106, 
123, 220, 221] and localises in the PrPSc region that typically remains after 
proteolytic cleavage, we proposed that H95 may have a role in PrPSc formation. In 
agreement with this hypothesis, H95Y mutant expressed in N2aPrP-/- 
spontaneously converted into PrPres that had seeding activity in ASA and it was 
detected by PMCA.       
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The question is why H95Y mutant can cause spontaneous conversion. 
Structural studies revealed that the N-terminal of the prion protein (residue 23-127) 
is highly disordered [115] without any regular secondary structure [222, 223]. 
Therefore, instead of causing a significant change in structure like other pathogenic 
mutations in the globular domain, H95Y might alter the interaction between distinct 
portions in the protein structure, whose changes are required for oligomerization 
into fibrillar species. This hypothesis was supposed by a recent publication by 
Thakur and colleagues [224]. In this study, they found that copper bound to PrP 
could induce interactions between N- and C-terminal regions, in which  the N-
terminal region (residues 90–120) became proximal to helix-1 (residues 144–147) 
and its nearby loop region (residues 139–143). These regions were shown to 
promote aggregation [225-227] and the helix-1 region also played a prominent role 
in prion replication [228]. Therefore, they proposed that the interactions between 
these regions and the N-terminal region (residues 90–120) might regulate prion 
conversion. In this study, we found that H95Y mutant caused a modification on 
Cu(II) coordination in the non-OR region. In PrP WT Cu(II) was anchored to two 
histidine at pH 5.5, and only one histidine at pH 7. Conversely, in H95Y mutants 
copper was bound only to one histidine independently of the pH. This might lead 
to the change of aforementioned interactions, promoting prion replication.  
In addition, our analysis showed that H95Y mutant induced PrPC 
accumulation in the acidic endosomal compartments, a putative site for prion 
conversion. Therefore, the alteration of copper coordination of H95Y mutant seems 
corresponding to its accumulation in acidic endosomes. Taken together, we 
proposed a model in which the copper binding had a protective role in prion 
conversion. In acidic condition, copper bound to non-OR region might stabilize this 
segment when coordinated by H95 and H110, inducing transient short or long range 
interactions between C-terminal domain and N-terminal region, such as an 
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interaction between residues 90–120 and residues 139-147 (including helix-1 and 
its nearby loop region), preventing the conversion from PrPC to PrPSc. Copper might 
act as a key modulator of this process since the removal of copper led to promoted 
prion conversion, as observed in CPZ-treatment experiments.  
 
Figure 30. Model for the non-OR region molecular switch at acidic pH. In 
acidic conditions as endosomal compartments, PrPC binds “tightly” to copper in the 
non-OR region hinder the conversion from PrPC to PrPSc. When PrPC binds 
“loosely” or doesn’t bind to copper in non-OR region, PrPC is more prone to the 
conversion.  As PrPSc model we used the HET-s (218-289) 2KJ3 PDB structure. 
In this study, we also investigated the copper coordination in the pathogenic 
mutations P101L and Q211P. Q211P mutation situates in C-terminal globular 
domain and is responsible for a rare GSS syndrome characterized by mild amyloid 
PrP deposition in patients [229]. This mutation induces prominent structural 
differences, including disruption of the C-terminal part of the α3 helix, solvent 
exposure of hydrophobic residues and a different orientation of α2 and α3 helices. 
These changes lead to th reduction of the PrP stability and promote the prion 
conversion [168]. P101L locates in the flexible N-terminus of PrP and is the most 
common mutation associated with the GSS disease. Differently from C-terminal 
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pathogenic mutations, P101L has no or little effect on the thermodynamic stability 
of PrP [172] but influences the structure and propagation of PrPSc [229, 230]. 
Although their impacts on the structure and stability of PrP are different, they 
interestingly share the same copper coordination on non-OR region, in which 
copper is bound only to H110 at both pH 5.5 and 7.0, similar to H95Y mutant. 
These data suggest that in addition to thermodynamic destabilization, the alteration 
of copper binding in non-OR region might also contribute to promoting 
spontaneous generation of prions of Q211P mutant. In case of P101L mutation, 
while other structural studies revealed no significant difference between WT and 
its structure [231], based on the perturbation of the copper coordination in the non-
OR region, our models may appropriately explain why this mutation cause disease. 
Moreover, the data from these mutations strongly support our hypothesis about the 
role of non-OR region as molecular switch for prion conversion. 
Based on this model, not only H95 but H110 might have a similar role in 
prion conversion. In our results, the H110Y and H95Y/H110Y mutant expressed in 
N2aPrP-/- cells also converted spontaneously into PrPres, which can be detected by 
ASA. On the other hand, substituting H95 by all possible amino acids, we found 
that the effect of these mutants on prion conversion has a large fluctuation and 
seems to depend on the substitute’s hydrophobicity. The hydrophobic amino acids 
promoted, while the charged amino acids inhibited conversion. This revealed that 
H95 could be an important “hot spot” for prion conversion, as this site might acts 
as a molecular switch that can “turn on” or “turn off” prion conversion. Considering 
the proposed model, we think that these mutants might differently change copper 
coordination leading to different effects on PrPSc formation; therefore further 
studies on copper coordination of these mutants are needed to explore this issue. 
Moreover it will be very interesting if we consider the role of other metals. 
Other metals have been suggested to bind to PrPC, these include manganese, zinc, 
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and nickel [35, 124, 138, 232-234]. Recombinant PrP has been shown to bind to 
manganese in vitro, and the binding of manganese to PrP potentially results in the 
conversion of the protein to an abnormal isoform with properties reminiscent of 
PrPSc [234, 235]. In particular, manganese-bound PrP shows greater protease 
resistance [236], increased β-sheet content, the ability to aggregate [237], and the 
ability to seed polymerization of prion protein [235]. Interestingly, prion infected 
mice have dramatic differences in blood, muscle, and brain metal content as 
compared to the non-infected mice [238]. These infected mice showed increased 
manganese and decreased copper content. Thus, it has been suggested that 
substitution of copper with manganese could bring about changes in PrP, initiating 
prion disease [234]. Brazier et al. (2008) [239] indicated that the main manganese 
binding site is associated with H95. Therefore, manganese may be related to the 
role of the fifth copper binding site. Because manganese binds to H95 at a lower 
affinity than copper, the binding of copper precedent here was in a normal 
condition. The adjustment in copper coordination might lead to the replacement of 
copper with manganese, promoting the conversion of PrPC to PrPSc. Considering 
that the dual impact of these metals might bring about a better answer for the role 
of H95 in prion conversion. 
We also used a new Tg mice expressing the H95Y mutant. The preliminary 
results showed that these Tg mice spontaneously developed prion diseases as they 
showed clinical signs with a shortened lifespan and they present PK-resistant PrPres 
in brain. Interestingly, Tg mice with low expression level of H95Y mutant also 
developed diseases. Although, these experiments are still ongoing and further 
analyses will be carried out, these preliminary results clearly point to an important 
role of H95 in prion conversion. In addition, these Tg mice may be useful for further 
studying of the relationship between copper and prion disease and also for studying 
physiological functions of the fifth copper binding site. Moreover, the non-OR 
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region has recently been found as the principal site for amyloid-β peptide (Aβ) 
oligomer binding and modulating Aβ neurotoxicity [240]. Therefore, H95YMoPrP 
Tg mice can be used as an animal model for investigating the interaction between 
the non-OR region and Aβ oligomers to possibility define a relation among copper, 
PrPC function and oligomeric Aβ in neurodegenerative disorders. 
In conclusion, our findings in this work provide valuable evidences for the 
critical role of the non-OR copper-binding site in prion conversion. In this work, by 
using ScN2a cell conversion assay, we found that H95Y mutant promoted PrPSc 
formation, and this mutant accumulated in the acidic endosomal compartments. 
Here we also used EXAFS method to define the copper coordination in non-OR 
region of WT and H95Y mutant. The difference of these coordination revealed the 
role of copper binding in this region to PrPSc formation. Based on these data, we 
proposed the model, in which the non-OR region acts as a critical molecular 
“switch” for prion conversion with copper as a modulator. The tight binding of 
copper in non-OR region induces transient interaction between C-and N-terminal 
domain, and prevents the conversion from PrPC to PrPSc. The loose binding or 
absence of copper lead to the opposite effect that accelerated the PrPSc formation. 
The EXAFS data from P101L and Q211P mutations shared similar behavior of non-
OR copper coordination and they were highly in line with the proposed model. In 
addition, this model was proven by the results from N2aPrP-/- cells expressing non-
OR mutants. The non-OR mutants on these cells could spontaneously convert into 
PrPres molecules at detectable level of ASA and PMCA method. We also estabished 
Tg mice expressing H95Y mutant as in vivo model for examing our hyposthesis. 
Interestingly, in preliminary results, these Tg mice also developed diseases, 
providing an additional evidence for a pivotal role of non-OR region in prion 
conversion. These findings are remarkable because this is the first time that a 
proposed mechanism of prion conversion has been described at biochemical, 
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structural and functional level. This hypothesis should be considered when studying 
the pathogenic point mutations, especially the N-terminal mutations.  
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APPENDIX 
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A. The 3F4–epitope tag has no effect on prion conversion  
The 3F4-epitope tag is a powerful tool to distinguish between exogenous 
and endogenous MoPrPs. To confirm that this tag has no effect on prion 
replication, we transiently transfected ScN2a cells with vector 
pcDNA::MoPrP(1-254)WT or pcDNA::MoPrP(1-254)WT3F4. 72 hours after 
transfection, cell lysates were collected and treated with PK to evaluate PrPSc 
PK-resistance levels. Immunoblotting with anti-PrP W226 antibody showed the 
similarity in PK-resistance PrPSc levels between cells expressing PrP WT with 
and without 3F4-tag (Figure S1).    
 
Figure S1. The 3F4–epitope tag has no effect on prion conversion. For non-PK 
experiment, fifty μg of undigested lysates was applied to each lane, β-actin was used 
as internal control. For PK experiment, five hundred μg of cell lysates was digested 
with PK (20 μg/mL) at 37 °C for 1 hour. PrPs were detected by anti-PrP W226 mAb. 
B. PrP mutants with the substitution of histidine by tyrosine are not toxic to 
ScN2a cells  
To evaluate the toxicity of mutants, ScN2a were transfected with MoPrP 
constructs. Seventy-two hours after the transfection, the medium was removed 
and the MTT assay was performed as described. The result showed that all cells 
shared a similar viability, around 100 % compared to un-transfected cells 
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(Figure S2). This indicated that the expressions of WT3F4 and mutants had no 
toxicity effect on ScN2a cells.   
 
Figure S2. The histidine substitutions in the OR and non-OR regions are not 
toxic for cell culture.  
C. Substitution of histidine by tyrosine at H110 leads to destroy 3F4 epitope 
His residue 110 is located inside the 3F4 epitope. So substitution of 
His110 will change the amino acid sequences of this region, destroying the 
epitope, thus anti-3F4 antibody cannot recognize it. To examining this, we 
created two constructs with the replacement of histidine by tyrosine at H110. 
These constructs were transfected into N2a cell, and their expression was 
checked by western blot using anti-3F4 antibody.  
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Figure S3. Substitution of histidine by tyrosine at H110 leads to destroy 3F4 
epitope. Fifty μg of cell lysates was applied to each lane, β-actin was used as 
internal control. PrPs were detected by anti-PrP 3F4 mAb. 
In positive control sample, MoPrP WT3F4 was recognized, showing 
clear signal on immunoblot membrane. In contrast, H110Y3F4 and 
H95Y/H110Y3F4 constructs were not recognized by anti-3F4 antibody in this 
experiment. Therefore, 3F4 tag cannot be used for studies in which His110 is 
replaced by other amino acid.     
D. Copper coordination in the non-OR region of pathogenic mutants P101L 
and Q211P 
The structures of Cu(II) and Cu(I) binding sites were investigated in Q211P 
and P101L HuPrP mutants at both pH 5.5 and 7.0 values. The EXAFS data of the 
mutants share the same coordination pattern observed for the WT at pH 7.0, where 
the copper ion is coordinated by a single His, namely H110 (Figure S4AB). While 
in the WT the copper ion -at both oxidative states- changes coordination losing the 
contact with H95 at pH 7.0, in the pathogenic mutants copper is bound only to H110 
independently of the pH. 
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Figure S4. Comparison between copper coordination of pathological P101L, 
Q211P and HuPrP WT. (A) k3-weighted EXAFS spectra and Fourier transforms 
of Cu(II) and Cu(I) bound to HuPrP(90-231) WT and Q211P at pH 5.5 and 7.0 
and (B) of Cu(II) and Cu(I) bound to WT HuPrP(90-231) and P101L at pH 5.5 and 
7.0. (C) Schematic representations of copper binding sites in the HuPrP(90-231) 
Q211P and P101L. 
E. Expression and purification of recombinant PrP  
All MoPrP and HuPrP variants were cloned into plasmid pET11a. The 
recombinant proteins were produced in E. coli BL21(DE3) in LB medium. As a 
reference, here we showed results of the MoPrP23-231 WT only. 
Large-scale protein expression was achieved using a 2 L bioreactor which 
allowed an automated pH, stirrer, temperature and pO2 control. Fermentation was 
carried out at 37 oC, pH 7.0 and pO2 30 %. The fermentation profile was presented 
in Figure S5. At the end of the fermentation process, bacterial yield was 9-10 g/L 
of paste with a final OD600 nm of 7-8. By using 1 mM IPTG as inducer, MoPrP 
was overexpressed in bacterial cells with clear band in SDS-PAGE (Figure S5). 
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Figure S5. Fermentation and expression of MoPrP23-231 in E. coli BL21 
(DE3). (A) Profile of fermentation process. (B) Expression of MoPrP23-231 in E. 
coli BL21 (DE3), t0: before induction, t16: 16 hours after induction. 
MoPrP23-231 were expressed in BL21(DE3) as insoluble inclusion bodies. 
Therefore they needed to be solubilized in in 8 M GndHCl and purified under 
denature condition. MoPrP23-231 contains muti-His region in N-terminal, so it can 
bind to metals as copper, nikel...  Rely on this characteristic, MoPrP23-231 were 
first purified by Immobilized metal ion affinity chromatography (IMAC) using 
Histrap column.  After the first purification step (Figure S6A), the proteins were 
considerably pure with only a small number of contaminant bands. Fractions 
containing PrP from this step were loaded into SEC column to obtain a highly 
purified protein (Figure S6B). 
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Figure S6. Purification of MoPrP23-231. (A) Purification of MoPrP23-231 by 
Histrap column, (B) Purification of MoPrP23-231 by Size exclusion 
chromatography. 
F. Establishment of Tg mice expressing MoPrP H95Y 
MoPrP H95Y-coding sequences were inserted into pJB1, resulting in 
plasmid pJB::MoPrP(1-254, H95Y). MoPrP mutant transgenes (H95Y) containing 
mouse regulatory sequences were excised from the plasmid pJB::MoPrP(1-254, 
H95Y) by using the restriction endonuclease NotI. These fragments were then 
microinjected into the pronucleus of fertilized FVB mice eggs, which were 
implanted into pseudopregnant FVB females. DNA prepared from tail of F0 
offspring mice was used to screen for transgene integration by a PCR assay. 
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Figure S7. Maps of plamid pJB::MoPrP(1-254, H95Y). 
Two PCR assay were used to screen and confirm the integration of transgene 
into F0 mice genome.  
 PCR assay 1: 
- Transgene PCR primer F1: GAA CTG AAC CAT TTC AAC CGA G 
- Transgene PCR primer R1: AGA GCT ACA GGT GGA TAA CC 
- Internal control PCR primer F: ACT CCA AGG CCA CTT ATC ACC 
- Internal control PCR primer R: ATT GTT ACC AAC TGG GAC GAC A 
- Annealing Temp: 55 oC 
- Transgene PCR product size: 800 bp 
- Internal control PCR product size: 413 bp 
 PCR assay 2: 
- Transgene PCR primer F2: TGG CGA ACC TTG GCT ACT G  
- Transgene PCR primer R2: GTG ATA TTG ACG CAG TCG TGC  
- Internal control PCR primer F: ACT CCA AGG CCA CTT ATC ACC  
- Internal control PCR primer R: ATT GTT ACC AAC TGG GAC GAC A  
- Annealing Temp: 62 oC  
- Transgene PCR product size: 550 bp  
- Internal control PCR product size: 413 bp 
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Figure S8. PCR assay for screening Tg mice. (A) PCR assay 1. (B) PCR assay 2. 
The internal control PCR targets the endogenous mouse Actb (beta-actin) locus. 
Positive control is 400 ng of mouse genomic DNA spiked with an amount of 
transgene injection DNA that is equivalent to 5 copies of transgene per diploid 
mouse genome. Wild-type control is 400 ng of mouse genomic DNA. 
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